<drug type="biotech" created="2005-06-13" updated="2021-01-01">
  <drugbank-id primary="true">DB00030</drugbank-id>
  <drugbank-id>BTD00105</drugbank-id>
  <drugbank-id>BIOD00105</drugbank-id>
  <drugbank-id>DB01383</drugbank-id>
  <drugbank-id>DB05278</drugbank-id>
  <drugbank-id>DB05215</drugbank-id>
  <drugbank-id>DB05283</drugbank-id>
  <drugbank-id>DB08914</drugbank-id>
  <name>Insulin human</name>
  <description>Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions.&#13;
&#13;
Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as [DB00331], [DB01120], or [DB01261] have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. &#13;
&#13;
Marketed as the brand name product Humulin R or Novolin R, human insulin begins to exert its effects within 30 minutes of subcutaneous administration, while peak levels occur 3-4 hours after administration. Due to its quick onset of action, human insulin is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as [DB01307], [DB09564], and [DB00047] to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia.&#13;
&#13;
Human insulin is also available in an inhalable form, intended to be used as a bolus meal-time insulin. Exubera was the first inhaled insulin available on the market and was developed by Inhale Therapeutics (later named Nektar Therapeutics). Unfortunately, limited uptake by physicians and patients, poor sales, bulky packaging, and concerns over the possible impact on lung cancer development resulted in Exubera products being withdrawn from the US markets [A176005]. Exubera was followed by Afrezza, a monomeric inhaled insulin developed by Mannkind Corporation, which received FDA approval in 2016. While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease. Afrezza does not currently have Health Canada or European Medicines Agency approval for marketing in Canada or the EU. &#13;
&#13;
Human Insulin is a 51 residue peptide hormone produced by recombinant DNA technology by inserting the human insulin gene into Escherichia coli bacteria or Saccharomyces cerevisiae. The structure is identical to native human insulin, with two amino acid chains covalently linked by disulfide bonds. &#13;
&#13;
Human insulin is also available in an intermediate-acting form as NPH (Neutral Protamine Hagedorn) as the marketed products Novolin N and Humulin N. NPH insulin is provided as a crystalline suspension of insulin with protamine and zinc, resulting in an onset of action in 1 to 3 hours, duration of action up to 24 hours, and peak action from 6 to 8 hours. Due to the added crystals, NPH insulin is typically cloudy when compared to other forms of insulin and has a neutral pH.&#13;
&#13;
Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy.</description>
  <cas-number>11061-68-0</cas-number>
  <unii>1Y17CTI5SR</unii>
  <state>liquid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A40</ref-id>
        <pubmed-id>23512415</pubmed-id>
        <citation>Herrmann BL, Kasser C, Keuthage W, Huptas M, Dette H, Klute A: Comparison of insulin aspart vs. regular human insulin with or without insulin detemir concerning adipozytokines and metabolic effects in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2013 Apr;121(4):210-3. doi: 10.1055/s-0033-1334905. Epub 2013 Mar 19.</citation>
      </article>
      <article>
        <ref-id>A41</ref-id>
        <pubmed-id>11118018</pubmed-id>
        <citation>Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000 Dec;49(12):2142-8.</citation>
      </article>
      <article>
        <ref-id>A42</ref-id>
        <pubmed-id>10841002</pubmed-id>
        <citation>Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R: Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000 Jun;23(6):813-9.</citation>
      </article>
      <article>
        <ref-id>A43</ref-id>
        <pubmed-id>14578244</pubmed-id>
        <citation>Danne T, Lupke K, Walte K, Von Schuetz W, Gall MA: Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care. 2003 Nov;26(11):3087-92.</citation>
      </article>
      <article>
        <ref-id>A44</ref-id>
        <pubmed-id>18715209</pubmed-id>
        <citation>Owens DR, Bolli GB: Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. Diabetes Technol Ther. 2008 Oct;10(5):333-49. doi: 10.1089/dia.2008.0023.</citation>
      </article>
      <article>
        <ref-id>A176005</ref-id>
        <pubmed-id>27574374</pubmed-id>
        <citation>Oleck J, Kassam S, Goldman JD: Commentary: Why Was Inhaled Insulin a Failure in the Market? Diabetes Spectr. 2016 Aug;29(3):180-4. doi: 10.2337/diaspect.29.3.180.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L12516</ref-id>
        <title>FDA Approved Drug Products: Humulin R (insulin human)</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018780s126s134lbl.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference>Humulin is synthesized in a special non-disease-producing laboratory strain of Escherichia coli bacteria that has been genetically altered to produce human insulin.</synthesis-reference>
  <indication>Human insulin is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.</indication>
  <pharmacodynamics>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). </pharmacodynamics>
  <mechanism-of-action>The primary activity of insulin is the regulation of glucose metabolism. Insulin promotes glucose and amino acid uptake into muscle and adipose tissues, and other tissues except brain and liver. It also has an anabolic role in stimulating glycogen, fatty acid, and protein synthesis. Insulin inhibits gluconeogenesis in the liver.&#13;
Insulin binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor is able to autophosphorylate and phosphorylate numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. These activated proteins, in turn, lead to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC) which play a critical role in metabolism and catabolism.</mechanism-of-action>
  <toxicity/>
  <metabolism>The metabolism and elimination of orally inhaled human insulin are comparable to regular human insulin.</metabolism>
  <absorption>When injected subcutaneously, the glucose-lowering effect of human insulin begins approximately 30 minutes post-dose. After a single subcutaneous administration of 0.1 unit/kg of human insulin to healthy subjects, peak insulin concentrations occurred between 1.5 to 2.5 hours post-dose. &#13;
&#13;
When administered in an inhaled form (as the product Afrezza), the time to maximum serum insulin concentration ranges from 10-20 minutes after oral inhalation of 4 to 48 units of human insulin. Serum insulin concentrations declined to baseline by approximately 60-240 minutes for these dose levels. Intrapatient variability in insulin exposure measured by AUC and Cmax is approximately 16% (95% CI 12-23%) and 21% (95% CI 16-30%), respectively.</absorption>
  <half-life>Systemic insulin disposition (apparent terminal half-life) following oral inhalation of 4 to 48 units of human insulin was 120-206 minutes.</half-life>
  <protein-binding/>
  <route-of-elimination>Following oral inhalation of human insulin, a mean of 39% of the inhaled dose of carrier particles was distributed to the lungs and a mean of 7% of the dose was swallowed. The swallowed fraction was not absorbed from the GI tract and was eliminated unchanged in the feces.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001733</drugbank-id>
      <name>Insulin human zinc suspension</name>
      <unii/>
      <cas-number/>
      <inchikey/>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001734</drugbank-id>
      <name>NPH insulin</name>
      <unii/>
      <cas-number>53027-39-7</cas-number>
      <inchikey/>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">High molecular weight insulin human</synonym>
    <synonym language="english" coder="">Human insulin</synonym>
    <synonym language="english" coder="">human insulin (rDNA)</synonym>
    <synonym language="english" coder="">Insulin (human)</synonym>
    <synonym language="english" coder="inn/ban/usan/usp">Insulin human</synonym>
    <synonym language="english" coder="">Insulin human [rDNA origin]</synonym>
    <synonym language="english" coder="">Insulin Human Regular</synonym>
    <synonym language="english" coder="">Insulin human regular (rDNA)</synonym>
    <synonym language="english" coder="">Insulin human, rDNA origin</synonym>
    <synonym language="english" coder="">Insulin recombinant human</synonym>
    <synonym language="english" coder="">Insulin recombinant purified human</synonym>
    <synonym language="english" coder="">Insulin regular</synonym>
    <synonym language="english" coder="">Insulin, human</synonym>
    <synonym language="spanish" coder="">Insulina regular</synonym>
    <synonym language="english" coder="">Regular Insulin, human</synonym>
  </synonyms>
  <products>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/001</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/002</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/003</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/004</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/036</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/037</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/033</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/034</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/035</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/030</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/031</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/032</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/011</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/012</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 30 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/013</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 40 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/014</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 40 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/015</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 40 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/016</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/017</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/018</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actraphane 50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000427</ema-product-code>
      <ema-ma-number>EU/1/02/229/019</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/001</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/002</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/003</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/004</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/016</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/017</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/013</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/014</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/015</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/010</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/011</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/012</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/005</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/006</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Actrapid Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000424</ema-product-code>
      <ema-ma-number>EU/1/02/230/007</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Powder, metered</dosage-form>
      <strength>4 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Powder, metered</dosage-form>
      <strength>8 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-840</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2014-10-22</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5874</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Powder, metered</dosage-form>
      <strength>4 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Sanofi Aventis</labeller>
      <ndc-id/>
      <ndc-product-code>0024-5894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2017-11-07</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-882</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-894</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2016-08-03</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on>2016-08-03</ended-marketing-on>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>NDA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-874</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>4 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-878</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>8 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-891</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, metered</dosage-form>
      <strength>12 1/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-880</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Afrezza</name>
      <labeller>Mannkind Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>47918-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number>BLA022472</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Entuzity Kwikpen</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466864</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Exubera</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0707</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, powder</dosage-form>
      <strength>1 mg/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exubera</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0724</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Aerosol, powder</dosage-form>
      <strength>3 mg/1</strength>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exubera</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Exubera</name>
      <labeller>Pfizer Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0069-0050</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2008-04-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength/>
      <route>Respiratory (inhalation)</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humalog 70/30</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2746</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-12-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 10/90 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962639</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 10/90 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962639</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 10/90 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889113</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 10/90 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889113</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-03</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 20/80 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962655</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-27</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 20/80 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962655</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2006-07-27</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 20/80 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889105</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 20/80 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889105</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 30/70 (insulin Human Biosynth Inj)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00795879</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 30/70 (insulin Human Biosynth Inj)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00795879</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 30/70 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959212</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 30/70 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959212</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 40/60 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962647</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-26</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 40/60 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962647</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-26</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 40/60 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889091</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 40/60 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889091</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 50/50</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-9515</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-05-18</started-marketing-on>
      <ended-marketing-on>2010-05-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA020100</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 50/50 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962663</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-26</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 50/50 Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01962663</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2002-07-26</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 50/50 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889121</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 50/50 Inj</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00889121</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2001-08-02</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0444</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8770</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-10</started-marketing-on>
      <ended-marketing-on>2007-09-10</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8715</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1989-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30 70/30</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>52125-415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-27</started-marketing-on>
      <ended-marketing-on>2016-02-22</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin 70/30 KwikPen</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8803</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019717</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin L</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8415</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1985-09-30</started-marketing-on>
      <ended-marketing-on>2007-02-01</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019377</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-1429</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-10-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0352</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8730</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-09-10</started-marketing-on>
      <ended-marketing-on>2007-09-10</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8315</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8805</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-11-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA018781</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin N</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00587737</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength>100 unit/mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin N (cartridge)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959239</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin N (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02403447</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-09-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3619</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0353</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Parenteral</route>
      <fda-application-number>NDA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8215</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Parenteral</route>
      <fda-application-number>BLA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00586714</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1983-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>100 unit/mL</strength>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin R (kwikpen)</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02415089</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin R Cartridge</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>01959220</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1992-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Humulin R U-500</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8501</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1994-03-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin R U-500 KwikPen</name>
      <labeller>Eli Lilly and Company</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>500 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA018780</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Humulin U</name>
      <labeller>Eli Lilly &amp; Co. Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>0002-8615</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-06-10</started-marketing-on>
      <ended-marketing-on>2007-07-01</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019571</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/001</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/002</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/003</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/004</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/016</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/017</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/013</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/014</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Flexpen</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/015</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/010</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/011</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Innolet</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/012</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/005</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/006</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulatard Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000441</ema-product-code>
      <ema-ma-number>EU/1/02/233/007</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 iu/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/003</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/004</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/020</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/021</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/022</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/023</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/024</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/089</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/094</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/099</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/119</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/120</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/121</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/122</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/123</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/124</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/171</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/172</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/005</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/006</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/029</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/030</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/031</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/032</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/033</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/090</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/095</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/100</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/125</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/126</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/127</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/128</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/129</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/130</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/007</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/008</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/038</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/039</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/040</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/041</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/042</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/091</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/096</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/101</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/131</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/132</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/133</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/134</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/135</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/136</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/143</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/144</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/145</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/146</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/147</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/148</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/149</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/150</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/163</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/164</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/165</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/166</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/167</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/168</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/173</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/174</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/009</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/010</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/047</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/048</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/049</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/050</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/051</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/092</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/097</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/102</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/137</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/138</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/139</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/140</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/141</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/142</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Infusat</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/056</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Infusat</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/057</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/001</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/002</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/011</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/012</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/013</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/014</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/015</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/088</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/093</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/098</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/113</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/114</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/115</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/116</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/117</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/118</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/169</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insulin Human Winthrop Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000761</ema-product-code>
      <ema-ma-number>EU/1/06/368/170</ema-ma-number>
      <started-marketing-on>2007-01-17</started-marketing-on>
      <ended-marketing-on>2018-04-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/033</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/034</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/035</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/036</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/037</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/057</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/058</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/069</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/070</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/071</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/072</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/086</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/091</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/096</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/101</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/106</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/116</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/117</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/118</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/119</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/120</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/121</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/146</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/147</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/148</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/149</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/150</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/151</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/198</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Basal</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/199</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/038</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/039</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/040</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/041</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/042</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/059</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/060</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/073</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/074</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/075</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/076</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/087</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/092</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/097</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/102</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/107</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/122</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/123</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/124</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/125</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/126</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/127</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/152</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/153</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/154</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/155</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/156</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 15</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/157</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/043</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/044</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/045</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/046</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/047</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/061</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/062</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/077</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/078</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/079</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/080</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/088</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/093</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/098</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/103</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/108</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/128</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/129</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/130</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/131</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/132</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/133</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/158</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/159</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/160</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/161</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/162</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 25</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/163</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/170</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/171</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/172</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/173</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/174</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/175</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/176</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/177</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/178</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/179</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/180</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/181</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/182</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/183</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/184</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/185</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/186</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/187</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/188</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/189</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/190</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/191</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/192</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/193</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/194</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/195</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/200</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 30</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/201</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/048</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/049</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/050</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/051</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/052</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/063</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/064</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/081</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/082</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/083</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/084</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/089</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/094</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/099</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/104</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/109</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/134</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/135</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/136</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/137</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/138</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/139</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/164</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/165</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/166</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/167</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/168</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Comb 50</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/169</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Implantable</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/202</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>400 IU/ml</strength>
      <route>Intraperitoneal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Implantable</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/203</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>400 IU/ml</strength>
      <route>Intraperitoneal</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Infusat</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/054</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Infusat</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/053</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/028</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/029</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/030</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/031</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/032</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>40 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/055</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/056</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/065</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/066</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/067</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/068</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/085</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/090</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/095</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/100</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/105</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/110</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/111</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/112</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/113</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/114</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/115</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/140</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/141</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/142</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/143</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/144</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/145</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/196</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Insuman Rapid</name>
      <labeller>Sanofi Aventis Deutschland Gmb H</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000201</ema-product-code>
      <ema-ma-number>EU/1/97/030/197</ema-ma-number>
      <started-marketing-on>1997-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Myxredlin</name>
      <labeller>Baxter Healthcare Corporation</labeller>
      <ndc-id/>
      <ndc-product-code>0338-0126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>1.00 [iU]/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>BLA208157</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3474</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>59060-1837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-15</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>A S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>54569-2918</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-1837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0403</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-713</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-05-24</started-marketing-on>
      <ended-marketing-on>2017-02-14</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3477</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on>2009-05-29</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-2317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2001-12-10</started-marketing-on>
      <ended-marketing-on>2009-05-29</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin 70/30</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024292</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2007-11-05</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024292</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2007-11-05</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024306</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2008-08-12</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024306</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on>2008-08-12</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024217</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024217</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025248</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 30/70 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025248</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 40/60 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024314</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 40/60 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024314</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 50/50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024322</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge 50/50 Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024322</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Nph</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024225</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Nph Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024268</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Toronto</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024233</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin Ge Toronto Penfill</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024284</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1993-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-2380</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2007-07-16</started-marketing-on>
      <ended-marketing-on>2011-11-30</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>59060-1834</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-15</started-marketing-on>
      <ended-marketing-on>2012-08-31</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-1834</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3474</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on>2009-05-29</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-2314</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on>2009-05-29</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1834</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin N</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0498</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-07-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-3598</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-06-30</started-marketing-on>
      <ended-marketing-on>2011-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59060-1833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-15</started-marketing-on>
      <ended-marketing-on>2012-06-30</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-1833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3473</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on>2009-03-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-2313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on>2009-03-31</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-0497</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-1701</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-1833</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1991-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin R</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code>0169-3003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>BLA019938</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolin70/30 70/30</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>52125-414</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-08</started-marketing-on>
      <ended-marketing-on>2015-06-09</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [USP'U]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019991</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>NovolinN N</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-651</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-07</started-marketing-on>
      <ended-marketing-on>2016-04-07</ended-marketing-on>
      <dosage-form>Injection, suspension</dosage-form>
      <strength>100 [iU]/1mL</strength>
      <route>Subcutaneous</route>
      <fda-application-number>NDA019959</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024446</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024446</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge Nph Inj Sus 100u/ml</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02024403</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Suspension</dosage-form>
      <strength/>
      <route>Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Novolinset Ge Toronto Inj Liq 100u/ml</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02025256</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1999-06-28</started-marketing-on>
      <ended-marketing-on>2005-08-04</ended-marketing-on>
      <dosage-form>Liquid</dosage-form>
      <strength/>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Velosulin</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000423</ema-product-code>
      <ema-ma-number>EU/1/02/232/001</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on>2009-04-17</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Velosulin</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000423</ema-product-code>
      <ema-ma-number>EU/1/02/232/002</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on>2009-04-17</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Velosulin</name>
      <labeller>Novo Nordisk</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000423</ema-product-code>
      <ema-ma-number>EU/1/02/232/003</ema-ma-number>
      <started-marketing-on>2002-10-07</started-marketing-on>
      <ended-marketing-on>2009-04-17</ended-marketing-on>
      <dosage-form>Injection, solution</dosage-form>
      <strength>100 IU/ml</strength>
      <route>Intravenous; Subcutaneous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Infusat</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Infusat</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulin Human Winthrop Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Infusat</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 15</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 25</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Rapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Basal</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Comb 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Implantable</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Implantable</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 40 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 50 Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30 Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actraphane 30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Actrapid</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Velosulin</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insuman Infusat</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Innolet</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard Flexpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Insulatard</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Exubera</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Exubera</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 50/50</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humalog 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin L</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin U</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>NovolinN N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin70/30 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Exubera</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Exubera</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 70/30 KwikPen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Afrezza</name>
      <ingredients>Insulin human + Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R U-500</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R U-500 KwikPen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin 70/30</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Myxredlin</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N (cartridge)</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Toronto</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Nph</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 40/60 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 40/60 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Nph Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 30/70</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 50/50 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 50/50 Penfill</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge Toronto Penfill</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N (kwikpen)</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 10/90 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 10/90 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 10/90 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 10/90 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 20/80 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 20/80 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 20/80 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 20/80 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 40/60 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 40/60 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 40/60 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 40/60 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 50/50 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 50/50 Inj</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 50/50 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 50/50 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 20/80 Penfill Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolin Ge 10/90 Penfill Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge Toronto Inj Liq 100u/ml</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge Nph Inj Sus 100u/ml</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Novolinset Ge 30/70 Inj Sus</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R (kwikpen)</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 30/70 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 30/70 Cartridge</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 30/70 (insulin Human Biosynth Inj)</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin 30/70 (insulin Human Biosynth Inj)</name>
      <ingredients>Insulin human + Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R Cartridge</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin R</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Humulin N</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
    <mixture>
      <name>Entuzity Kwikpen</name>
      <ingredients>Insulin human</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>A-S Medication Solutions LLC</name>
      <url>http://orders.a-smeds.com</url>
    </packager>
    <packager>
      <name>DispenseXpress Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>Eli Lilly &amp; Co.</name>
      <url>http://www.lilly.com</url>
    </packager>
    <packager>
      <name>Hospira Inc.</name>
      <url>http://www.hospira.com</url>
    </packager>
    <packager>
      <name>Intervet International</name>
      <url>http://www.intervet.ca</url>
    </packager>
    <packager>
      <name>Novo Nordisk Inc.</name>
      <url>http://www.novonordisk.com</url>
    </packager>
    <packager>
      <name>Pfizer Inc.</name>
      <url>http://www.pfizer.com</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Novo nordisk inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Novolin Ge Nph 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto 100 unit/ml</description>
      <cost currency="USD">2.14</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R 100 unit/ml</description>
      <cost currency="USD">2.29</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Nph Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.78</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin Ge Toronto Penfill 100 unit/ml Cartridge</description>
      <cost currency="USD">2.8</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin N Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Humulin R Cartridge 100 unit/ml Cartridge</description>
      <cost currency="USD">2.99</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>NovoLIN R InnoLet 100 unit/ml Solution 3ml Cartridge</description>
      <cost currency="USD">24.17</cost>
      <unit>cartridge</unit>
    </price>
    <price>
      <description>Novolin r 100 unit/ml cartridg</description>
      <cost currency="USD">33.33</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>NovoLIN R 100 unit/ml Solution 10ml Vial</description>
      <cost currency="USD">73.19</cost>
      <unit>vial</unit>
    </price>
    <price>
      <description>NovoLIN R PenFill 100 unit/ml Solution Five 3ml Cartridges Per Box = 15ml</description>
      <cost currency="USD">162.26</cost>
      <unit>cartridge</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Blood Glucose Lowering Agents</category>
      <mesh-id>D007004</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers</category>
      <mesh-id>D065694</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP1A2 Inducers (strength unknown)</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Enzyme Inducers</category>
      <mesh-id>D065693</mesh-id>
    </category>
    <category>
      <category>Drugs Used in Diabetes</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hormones</category>
      <mesh-id>D006728</mesh-id>
    </category>
    <category>
      <category>Hormones, Hormone Substitutes, and Hormone Antagonists</category>
      <mesh-id>D006730</mesh-id>
    </category>
    <category>
      <category>Hypoglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Insulin</category>
      <mesh-id>D007328</mesh-id>
    </category>
    <category>
      <category>Insulin, Short-Acting</category>
      <mesh-id>D061266</mesh-id>
    </category>
    <category>
      <category>Insulins and Analogues for Injection, Fast-Acting</category>
      <mesh-id/>
    </category>
    <category>
      <category>Pancreatic Hormones</category>
      <mesh-id>D010187</mesh-id>
    </category>
    <category>
      <category>Peptide Hormones</category>
      <mesh-id>D036361</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, suspension</form>
      <route>Cutaneous; Parenteral</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Cutaneous; Parenteral</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>100 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>40 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>30 IU/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>50 IU/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>100 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>40 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>100 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 IU/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>100 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>100 iu/ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>100 iu/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 IE</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 IE/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 I.E./ML</strength>
    </dosage>
    <dosage>
      <form/>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Respiratory (inhalation)</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>12 1/1</strength>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>4 1/1</strength>
    </dosage>
    <dosage>
      <form>Powder, metered</form>
      <route>Respiratory (inhalation)</route>
      <strength>8 1/1</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>3 ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>3 ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Aerosol, powder</form>
      <route>Respiratory (inhalation)</route>
      <strength>1 mg/1</strength>
    </dosage>
    <dosage>
      <form>Aerosol, powder</form>
      <route>Respiratory (inhalation)</route>
      <strength>3 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>10 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>20 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>40 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>50 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Parenteral</route>
      <strength>100 I.E./ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 I.E./ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>100 I.E./ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>1000 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>70 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>100 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 units/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>40 units/mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>30 IU</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>100 U/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>30 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>300 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>100 unit/mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>300 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>90 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route/>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral</route>
      <strength>100 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 unit/mL</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>500 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route/>
      <strength>100 iu/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route/>
      <strength>100 iu/ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>100 IU/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>100 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 IE/ML</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular; Parenteral</route>
      <strength>100 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous; Parenteral</route>
      <strength>100 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>100 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>40 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>100 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular</route>
      <strength>40 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Intramuscular; Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>40 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>100 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Subcutaneous</route>
      <strength>40 UI/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 I.E./ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route/>
      <strength>25 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>25 IU/mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>75 IU</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 IE</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intraperitoneal</route>
      <strength>400 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route/>
      <strength>300 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection</form>
      <route>Subcutaneous</route>
      <strength>30 %</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 IU/ml</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>30 iu/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, solution</form>
      <route>Intravenous</route>
      <strength>1.00 [iU]/1mL</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Subcutaneous</route>
      <strength>100 [USP'U]/1mL</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intravenous; Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Liquid</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral; Subcutaneous</route>
      <strength>40 IU/ML</strength>
    </dosage>
    <dosage>
      <form>Injection, suspension</form>
      <route>Parenteral</route>
      <strength>100 UI/ml</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Intramuscular; Intravenous; Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
    <dosage>
      <form>Suspension</form>
      <route>Subcutaneous</route>
      <strength>100 IU</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A10AC01">
      <level code="A10AC">Insulins and analogues for injection, intermediate-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AE01">
      <level code="A10AE">Insulins and analogues for injection, long-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AB01">
      <level code="A10AB">Insulins and analogues for injection, fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AD01">
      <level code="A10AD">Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="A10AF01">
      <level code="A10AF">Insulins and analogues for inhalation</level>
      <level code="A10A">INSULINS AND ANALOGUES</level>
      <level code="A10">DRUGS USED IN DIABETES</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>68:20.08</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00030.pdf?1553113572</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00030.pdf?1370754402</msds>
  <patents>
    <patent>
      <number>RE37872</number>
      <country>United States</country>
      <approved>2002-10-08</approved>
      <expires>2010-02-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2183577</number>
      <country>Canada</country>
      <approved>2007-10-30</approved>
      <expires>2015-02-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2253393</number>
      <country>Canada</country>
      <approved>2007-10-09</approved>
      <expires>2017-05-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7291132</number>
      <country>United States</country>
      <approved>2007-11-06</approved>
      <expires>2024-08-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6257233</number>
      <country>United States</country>
      <approved>2001-07-10</approved>
      <expires>2019-05-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6546929</number>
      <country>United States</country>
      <approved>2003-04-15</approved>
      <expires>2019-05-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6685967</number>
      <country>United States</country>
      <approved>2004-02-03</approved>
      <expires>2018-09-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6582728</number>
      <country>United States</country>
      <approved>2003-06-24</approved>
      <expires>2020-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8912193</number>
      <country>United States</country>
      <approved>2014-12-16</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7648960</number>
      <country>United States</country>
      <approved>2010-01-19</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6652885</number>
      <country>United States</country>
      <approved>2003-11-25</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8258095</number>
      <country>United States</country>
      <approved>2012-09-04</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8778403</number>
      <country>United States</country>
      <approved>2014-07-15</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>6444226</number>
      <country>United States</country>
      <approved>2002-09-03</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7943572</number>
      <country>United States</country>
      <approved>2011-05-17</approved>
      <expires>2026-08-10</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8119593</number>
      <country>United States</country>
      <approved>2012-02-21</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7943178</number>
      <country>United States</country>
      <approved>2011-05-17</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8889099</number>
      <country>United States</country>
      <approved>2014-11-18</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8623817</number>
      <country>United States</country>
      <approved>2014-01-07</approved>
      <expires>2029-09-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8389470</number>
      <country>United States</country>
      <approved>2013-03-05</approved>
      <expires>2020-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9192675</number>
      <country>United States</country>
      <approved>2015-11-24</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8215300</number>
      <country>United States</country>
      <approved>2012-07-10</approved>
      <expires>2022-11-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8146588</number>
      <country>United States</country>
      <approved>2012-04-03</approved>
      <expires>2023-04-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8950397</number>
      <country>United States</country>
      <approved>2015-02-10</approved>
      <expires>2021-07-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8485180</number>
      <country>United States</country>
      <approved>2013-07-16</approved>
      <expires>2030-03-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9283193</number>
      <country>United States</country>
      <approved>2016-03-15</approved>
      <expires>2026-09-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8636001</number>
      <country>United States</country>
      <approved>2014-01-28</approved>
      <expires>2032-07-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8424518</number>
      <country>United States</country>
      <approved>2013-04-23</approved>
      <expires>2031-10-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8551528</number>
      <country>United States</country>
      <approved>2013-10-08</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7464706</number>
      <country>United States</country>
      <approved>2008-12-16</approved>
      <expires>2023-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8729019</number>
      <country>United States</country>
      <approved>2014-05-20</approved>
      <expires>2028-12-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7305986</number>
      <country>United States</country>
      <approved>2007-12-11</approved>
      <expires>2023-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8499757</number>
      <country>United States</country>
      <approved>2013-08-06</approved>
      <expires>2032-02-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8156936</number>
      <country>United States</country>
      <approved>2012-04-17</approved>
      <expires>2023-01-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8734845</number>
      <country>United States</country>
      <approved>2014-05-27</approved>
      <expires>2030-06-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8227409</number>
      <country>United States</country>
      <approved>2012-07-24</approved>
      <expires>2031-03-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9393372</number>
      <country>United States</country>
      <approved>2016-07-19</approved>
      <expires>2029-07-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9339615</number>
      <country>United States</country>
      <approved>2016-05-17</approved>
      <expires>2029-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9511198</number>
      <country>United States</country>
      <approved>2016-12-06</approved>
      <expires>2030-02-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9597374</number>
      <country>United States</country>
      <approved>2017-03-21</approved>
      <expires>2031-10-08</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9358352</number>
      <country>United States</country>
      <approved>2016-06-07</approved>
      <expires>2031-02-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9446133</number>
      <country>United States</country>
      <approved>2016-09-20</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9662461</number>
      <country>United States</country>
      <approved>2017-05-30</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9717689</number>
      <country>United States</country>
      <approved>2017-08-01</approved>
      <expires>2026-09-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9943571</number>
      <country>United States</country>
      <approved>2018-04-17</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10046031</number>
      <country>United States</country>
      <approved>2018-08-14</approved>
      <expires>2029-08-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10201672</number>
      <country>United States</country>
      <approved>2019-02-12</approved>
      <expires>2030-08-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10342938</number>
      <country>United States</country>
      <approved>2019-07-09</approved>
      <expires>2029-06-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10500159</number>
      <country>United States</country>
      <approved>2019-12-10</approved>
      <expires>2030-11-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol. Alcohol may impair blood glucose control.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>Liraglutide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>Metreleptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The risk or severity of adverse effects can be increased when Pioglitazone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>Pramlintide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The risk or severity of congestive heart failure can be increased when Insulin human is combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00166</drugbank-id>
      <name>Lipoic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00974</drugbank-id>
      <name>Edetic acid</name>
      <description>Edetic acid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>Esmolol may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>Landiolol may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Enoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Pefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Rosoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Gatifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11404</drugbank-id>
      <name>Enrofloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Enrofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Delafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Benzthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Quinethazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Epitizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>Protriptyline may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>Amoxapine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>Trimipramine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>Amineptine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>Dimetacrine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>Butriptyline may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>Dosulepin may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>Tianeptine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>Oxaprotiline may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>Opipramol may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>Amitriptylinoxide may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>Dibenzepin may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>Quinupramine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>Melitracen may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>Lofepramine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>Iprindole may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>Imipramine oxide may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>Nortriptyline may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>Desipramine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Dapagliflozin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Canagliflozin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00294</drugbank-id>
      <name>Etonogestrel</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Etonogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00304</drugbank-id>
      <name>Desogestrel</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Desogestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00351</drugbank-id>
      <name>Megestrol acetate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Megestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Piperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00823</drugbank-id>
      <name>Ethynodiol diacetate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethynodiol diacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Sirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00977</drugbank-id>
      <name>Ethinylestradiol</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ethinylestradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01319</drugbank-id>
      <name>Fosamprenavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Fosamprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01357</drugbank-id>
      <name>Mestranol</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Mestranol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ephedra sinica root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01395</drugbank-id>
      <name>Drospirenone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Drospirenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Estrone sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Histrelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Hydroxyprogesterone caproate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09009</drugbank-id>
      <name>Articaine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Articaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09123</drugbank-id>
      <name>Dienogest</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Dienogest.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06343</drugbank-id>
      <name>Teprotumumab</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Teprotumumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00621</drugbank-id>
      <name>Oxandrolone</name>
      <description>Oxandrolone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>Testosterone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00984</drugbank-id>
      <name>Nandrolone phenpropionate</name>
      <description>Nandrolone phenpropionate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01185</drugbank-id>
      <name>Fluoxymesterone</name>
      <description>Fluoxymesterone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01420</drugbank-id>
      <name>Testosterone propionate</name>
      <description>Testosterone propionate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>Oxymetholone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06710</drugbank-id>
      <name>Methyltestosterone</name>
      <description>Methyltestosterone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06718</drugbank-id>
      <name>Stanozolol</name>
      <description>Stanozolol may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08804</drugbank-id>
      <name>Nandrolone decanoate</name>
      <description>Nandrolone decanoate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12461</drugbank-id>
      <name>GLPG-0492</name>
      <description>GLPG-0492 may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13169</drugbank-id>
      <name>Nandrolone</name>
      <description>Nandrolone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13587</drugbank-id>
      <name>Mesterolone</name>
      <description>Mesterolone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>Testosterone cypionate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>Testosterone enanthate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09270</drugbank-id>
      <name>Ubidecarenone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ubidecarenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Cibenzoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14025</drugbank-id>
      <name>Clinafloxacin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Clinafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00233</drugbank-id>
      <name>Aminosalicylic acid</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>Mesalazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>Sulfasalazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>Diflunisal may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>Salicylic acid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>Balsalazide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>Olsalazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Bismuth subsalicylate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>Dersalazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>Phenyl aminosalicylate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>Methyl salicylate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>Trolamine salicylate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>Nitroaspirin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>Aloxiprin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>Guacetisal may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>Carbaspirin calcium may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>Choline salicylate may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>Thiosalicylic acid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Sitagliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>Vildagliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>AMG-222 may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>Bisegliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Alogliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Saxagliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>Gosogliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>Linagliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>Dutogliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>Teneligliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>Omarigliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>Carmegliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>Gemigliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>Anagliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>Evogliptin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Exenatide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>Albiglutide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>Dulaglutide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Lixisenatide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>Semaglutide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>Taspoglutide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>Tranylcypromine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>Phenelzine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>Moclobemide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>Isocarboxazid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>Pargyline may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>Minaprine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>Iproniazid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>Nialamide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>Pirlindole may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>Toloxatone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>Hydracarbazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Methylene blue may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>Benmoxin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>Mebanazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>Octamoxin may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>Pheniprazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>Phenoxypropazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>Pivhydrazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>Safrazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>Caroxazone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>Furazolidone may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>Harmaline may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>Brofaromine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>Procaine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>Amphetamine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>Procarbazine may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>Linezolid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>Safinamide may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>Clorgiline may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Ethoxzolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00576</drugbank-id>
      <name>Sulfamethizole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00664</drugbank-id>
      <name>Sulfametopyrazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfametopyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sumatriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00891</drugbank-id>
      <name>Sulfapyridine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfapyridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01298</drugbank-id>
      <name>Sulfacytine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfacytine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01299</drugbank-id>
      <name>Sulfadoxine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01581</drugbank-id>
      <name>Sulfamerazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamerazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01582</drugbank-id>
      <name>Sulfamethazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04707</drugbank-id>
      <name>Hydroxyfasudil</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxyfasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06150</drugbank-id>
      <name>Sulfadimethoxine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadimethoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06821</drugbank-id>
      <name>Sulfameter</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfameter.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07996</drugbank-id>
      <name>5-(2-methylpiperazine-1-sulfonyl)isoquinoline</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08798</drugbank-id>
      <name>Sulfamoxole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamoxole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Vemurafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Azosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11389</drugbank-id>
      <name>Clorsulon</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Clorsulon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11461</drugbank-id>
      <name>Sulfachlorpyridazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfachlorpyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11462</drugbank-id>
      <name>Sulfaethoxypyridazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaethoxypyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11463</drugbank-id>
      <name>Sulfanitran</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfanitran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11464</drugbank-id>
      <name>Sulfaquinoxaline</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12051</drugbank-id>
      <name>Setrobuvir</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Setrobuvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12921</drugbank-id>
      <name>Chlorsulfaquinoxaline</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Chlorsulfaquinoxaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13214</drugbank-id>
      <name>Sulfadicramide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfadicramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13248</drugbank-id>
      <name>Phthalylsulfathiazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Phthalylsulfathiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13283</drugbank-id>
      <name>Sulfaisodimidine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaisodimidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13284</drugbank-id>
      <name>Meticrane</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Meticrane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13320</drugbank-id>
      <name>Sulfaperin</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaperin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13405</drugbank-id>
      <name>Mefruside</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Mefruside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13430</drugbank-id>
      <name>Mebutizide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Mebutizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13485</drugbank-id>
      <name>Sulfametomidine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfametomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13547</drugbank-id>
      <name>Sulfatolamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfatolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13556</drugbank-id>
      <name>Sulfamazone</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13580</drugbank-id>
      <name>Succinylsulfathiazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Succinylsulfathiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13617</drugbank-id>
      <name>Clorexolone</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Clorexolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13663</drugbank-id>
      <name>Clofenamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Clofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13699</drugbank-id>
      <name>Sulfathiourea</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfathiourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13708</drugbank-id>
      <name>Fenquizone</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Fenquizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13726</drugbank-id>
      <name>Sulfaguanidine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfaguanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13773</drugbank-id>
      <name>Sulfamethoxypyridazine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Sulfamethoxypyridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13792</drugbank-id>
      <name>Clopamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Clopamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14033</drugbank-id>
      <name>Acetyl sulfisoxazole</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Acetyl sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Fluvoxamine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Nicotine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Bortezomib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00201</drugbank-id>
      <name>Caffeine</name>
      <description>The metabolism of Caffeine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00262</drugbank-id>
      <name>Carmustine</name>
      <description>The metabolism of Carmustine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Lidocaine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00286</drugbank-id>
      <name>Conjugated estrogens</name>
      <description>The metabolism of Conjugated estrogens can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>The metabolism of Ropivacaine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The metabolism of Zolmitriptan can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Acetaminophen can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Chlorzoxazone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Mirtazapine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Mexiletine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The metabolism of Tacrine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>The metabolism of Triamterene can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The metabolism of Promazine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Zolpidem can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00442</drugbank-id>
      <name>Entecavir</name>
      <description>The metabolism of Entecavir can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The metabolism of Nabumetone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Fluoxetine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Duloxetine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Flutamide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00518</drugbank-id>
      <name>Albendazole</name>
      <description>The metabolism of Albendazole can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Rofecoxib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Cinnarizine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The metabolism of Diclofenac can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Imatinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The metabolism of Guanabenz can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00642</drugbank-id>
      <name>Pemetrexed</name>
      <description>The metabolism of Pemetrexed can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Verapamil can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Paroxetine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00730</drugbank-id>
      <name>Thiabendazole</name>
      <description>The metabolism of Thiabendazole can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The metabolism of Riluzole can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00744</drugbank-id>
      <name>Zileuton</name>
      <description>The metabolism of Zileuton can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Clopidogrel can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The metabolism of Acyclovir can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The metabolism of Naproxen can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The metabolism of Pentoxifylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The metabolism of Trifluoperazine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The metabolism of Perphenazine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Terbinafine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Ranitidine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The metabolism of Ethanol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The metabolism of Maprotiline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The metabolism of Alosetron can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The metabolism of Ramelteon can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Azathioprine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The metabolism of Frovatriptan can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>The metabolism of Levobupivacaine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Cinacalcet can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Selegiline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01056</drugbank-id>
      <name>Tocainide</name>
      <description>The metabolism of Tocainide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Praziquantel can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The metabolism of Melatonin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Primaquine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01094</drugbank-id>
      <name>Hesperetin</name>
      <description>The metabolism of Hesperetin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01097</drugbank-id>
      <name>Leflunomide</name>
      <description>The metabolism of Leflunomide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Cilostazol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Domperidone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Dexfenfluramine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01303</drugbank-id>
      <name>Oxtriphylline</name>
      <description>The metabolism of Oxtriphylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The metabolism of Rasagiline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01412</drugbank-id>
      <name>Theobromine</name>
      <description>The metabolism of Theobromine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Aminophenazone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Antipyrine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01482</drugbank-id>
      <name>Fenethylline</name>
      <description>The metabolism of Fenethylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The metabolism of Bromazepam can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The metabolism of Thiothixene can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Etoricoxib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Genistein can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01667</drugbank-id>
      <name>8-azaguanine</name>
      <description>The metabolism of 8-azaguanine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02134</drugbank-id>
      <name>Xanthine</name>
      <description>The metabolism of Xanthine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02489</drugbank-id>
      <name>9-Methylguanine</name>
      <description>The metabolism of 9-Methylguanine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02568</drugbank-id>
      <name>Peldesine</name>
      <description>The metabolism of Peldesine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Resveratrol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04076</drugbank-id>
      <name>Hypoxanthine</name>
      <description>The metabolism of Hypoxanthine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04356</drugbank-id>
      <name>9-Deazaguanine</name>
      <description>The metabolism of 9-Deazaguanine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Flunarizine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Lofexidine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04951</drugbank-id>
      <name>Pirfenidone</name>
      <description>The metabolism of Pirfenidone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Apremilast can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Mianserin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06210</drugbank-id>
      <name>Eltrombopag</name>
      <description>The metabolism of Eltrombopag can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06235</drugbank-id>
      <name>Vadimezan</name>
      <description>The metabolism of Vadimezan can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06479</drugbank-id>
      <name>Propentofylline</name>
      <description>The metabolism of Propentofylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Pazopanib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The metabolism of Agomelatine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Capsaicin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The metabolism of (R)-warfarin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>The metabolism of Perampanel can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The metabolism of Tasimelteon can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Stiripentol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The metabolism of Zotepine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The metabolism of Doxofylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The metabolism of Ramosetron can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11919</drugbank-id>
      <name>6-O-benzylguanine</name>
      <description>The metabolism of 6-O-benzylguanine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11967</drugbank-id>
      <name>Binimetinib</name>
      <description>The metabolism of Binimetinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12026</drugbank-id>
      <name>Voxilaprevir</name>
      <description>The metabolism of Voxilaprevir can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Triclabendazole can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Rucaparib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12406</drugbank-id>
      <name>Lisofylline</name>
      <description>The metabolism of Lisofylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12531</drugbank-id>
      <name>Lobucavir</name>
      <description>The metabolism of Lobucavir can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12926</drugbank-id>
      <name>Cafedrine</name>
      <description>The metabolism of Cafedrine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>The metabolism of Theodrenaline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The metabolism of Dihydralazine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13203</drugbank-id>
      <name>Bamifylline</name>
      <description>The metabolism of Bamifylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13449</drugbank-id>
      <name>Proxyphylline</name>
      <description>The metabolism of Proxyphylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13573</drugbank-id>
      <name>Acefylline</name>
      <description>The metabolism of Acefylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13592</drugbank-id>
      <name>Etamiphylline</name>
      <description>The metabolism of Etamiphylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13634</drugbank-id>
      <name>Pentifylline</name>
      <description>The metabolism of Pentifylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13812</drugbank-id>
      <name>Bufylline</name>
      <description>The metabolism of Bufylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Estradiol acetate can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Estradiol benzoate can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Estradiol cypionate can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Estradiol dienanthate can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Estradiol valerate can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14018</drugbank-id>
      <name>Bromotheophylline</name>
      <description>The metabolism of Bromotheophylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14132</drugbank-id>
      <name>8-chlorotheophylline</name>
      <description>The metabolism of 8-chlorotheophylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Nifedipine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Azelastine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Efavirenz can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05708</drugbank-id>
      <name>GTS-21</name>
      <description>The metabolism of GTS-21 can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Estradiol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The metabolism of Cyclobenzaprine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11689</drugbank-id>
      <name>Selumetinib</name>
      <description>The metabolism of Selumetinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00655</drugbank-id>
      <name>Estrone</name>
      <description>The metabolism of Estrone can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00299</drugbank-id>
      <name>Penciclovir</name>
      <description>The metabolism of Penciclovir can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The metabolism of Anagrelide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Sorafenib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Erlotinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The metabolism of Fluorouracil can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The metabolism of Tizanidine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Etoposide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00851</drugbank-id>
      <name>Dacarbazine</name>
      <description>The metabolism of Dacarbazine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01223</drugbank-id>
      <name>Aminophylline</name>
      <description>The metabolism of Aminophylline can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Dasatinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The metabolism of Acenocoumarol can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06769</drugbank-id>
      <name>Bendamustine</name>
      <description>The metabolism of Bendamustine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The metabolism of Pomalidomide can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Enasidenib can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Tamoxifen can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Gastric inhibitory polypeptide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Isradipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of hypoglycemia can be increased when Diltiazem is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of hypoglycemia can be increased when Trimethadione is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Amlodipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nimodipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nisoldipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lercanidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lamotrigine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>The risk or severity of hypoglycemia can be increased when Ethosuximide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nicardipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The risk or severity of hypoglycemia can be increased when Loperamide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nitrendipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Perhexiline is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of hypoglycemia can be increased when Bepridil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The risk or severity of hypoglycemia can be increased when Mibefradil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of hypoglycemia can be increased when Nimesulide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of hypoglycemia can be increased when Prenylamine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The risk or severity of hypoglycemia can be increased when Cyclandelate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of hypoglycemia can be increased when Fluspirilene is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Clevidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of hypoglycemia can be increased when Methsuximide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The risk or severity of hypoglycemia can be increased when Seletracetam is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of hypoglycemia can be increased when Nylidrin is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of hypoglycemia can be increased when Ziconotide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of hypoglycemia can be increased when Dotarizine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The risk or severity of hypoglycemia can be increased when Xylometazoline is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Nilvadipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hypoglycemia can be increased when Tranilast is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of hypoglycemia can be increased when Agmatine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Fendiline is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of hypoglycemia can be increased when Eperisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of hypoglycemia can be increased when Trimebutine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of hypoglycemia can be increased when Pinaverium is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Tolfenamic acid is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Barnidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Aranidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Azelnidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Benidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Cilnidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Darodipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Efonidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lacidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Manidipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Niguldipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Niludipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of hypoglycemia can be increased when Carboxyamidotriazole is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hypoglycemia can be increased when Naftopidil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of hypoglycemia can be increased when Tetrahydropalmatine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of hypoglycemia can be increased when Vinpocetine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Gallopamil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of hypoglycemia can be increased when Bencyclane is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of hypoglycemia can be increased when Otilonium is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of hypoglycemia can be increased when Terodiline is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lidoflazine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of hypoglycemia can be increased when Penfluridol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The risk or severity of hypoglycemia can be increased when Caroverine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The risk or severity of hypoglycemia can be increased when WIN 55212-2 is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The risk or severity of hypoglycemia can be increased when Fish oil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Dexverapamil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The risk or severity of hypoglycemia can be increased when Emopamil is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The risk or severity of hypoglycemia can be increased when Lomerizine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of hypoglycemia can be increased when Tetrandrine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Dexniguldipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The risk or severity of hypoglycemia can be increased when Felodipine is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The risk or severity of hypoglycemia can be increased when Amiodarone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The metabolism of Ropinirole can be increased when combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The therapeutic efficacy of Macimorelin can be decreased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Liothyronine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The risk or severity of adverse effects can be increased when Insulin human is combined with Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of hypoglycemia can be increased when Benazepril is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>The risk or severity of adverse effects can be increased when Testosterone undecanoate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Baclofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The risk or severity of hypoglycemia can be increased when Insulin human is combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00040</drugbank-id>
      <name>Glucagon</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Glucagon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bufuralol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bopindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Arotinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Levobetaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Anisodamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Mepindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Tertatolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The therapeutic efficacy of Betaxolol can be increased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The therapeutic efficacy of Propranolol can be increased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The therapeutic efficacy of Carvedilol can be increased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The therapeutic efficacy of Propafenone can be increased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The therapeutic efficacy of Insulin human can be increased when used in combination with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The therapeutic efficacy of Metoclopramide can be increased when used in combination with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Beclomethasone dipropionate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Betamethasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Triamcinolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fludrocortisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Mometasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The risk or severity of hyperglycemia can be increased when Corticotropin is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortisone acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Paramethasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Ciclesonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone furoate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednidene is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocortolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Meprednisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Dexamethasone isonicotinate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The risk or severity of hyperglycemia can be increased when Deflazacort is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortivazol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednylidene is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The risk or severity of hyperglycemia can be increased when Cloprednol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The risk or severity of hyperglycemia can be increased when Mometasone furoate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The risk or severity of hyperglycemia can be increased when Flunisolide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The risk or severity of hyperglycemia can be increased when Trilostane is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Budesonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The risk or severity of hyperglycemia can be increased when Aldosterone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednisolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The risk or severity of hyperglycemia can be increased when Melengestrol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The risk or severity of hyperglycemia can be increased when Cortisone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00223</drugbank-id>
      <name>Diflorasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Diflorasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00240</drugbank-id>
      <name>Alclometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Alclometasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00253</drugbank-id>
      <name>Medrysone</name>
      <description>The risk or severity of hyperglycemia can be increased when Medrysone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00288</drugbank-id>
      <name>Amcinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Amcinonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00324</drugbank-id>
      <name>Fluorometholone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluorometholone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00547</drugbank-id>
      <name>Desoximetasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Desoximetasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluticasone propionate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocinolone acetonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00596</drugbank-id>
      <name>Ulobetasol</name>
      <description>The risk or severity of hyperglycemia can be increased when Ulobetasol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00663</drugbank-id>
      <name>Flumethasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Flumethasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00838</drugbank-id>
      <name>Clocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Clocortolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00846</drugbank-id>
      <name>Flurandrenolide</name>
      <description>The risk or severity of hyperglycemia can be increased when Flurandrenolide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00896</drugbank-id>
      <name>Rimexolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Rimexolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01013</drugbank-id>
      <name>Clobetasol propionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasol propionate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01047</drugbank-id>
      <name>Fluocinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocinonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01130</drugbank-id>
      <name>Prednicarbate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednicarbate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01260</drugbank-id>
      <name>Desonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Desonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06781</drugbank-id>
      <name>Difluprednate</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluprednate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06786</drugbank-id>
      <name>Halcinonide</name>
      <description>The risk or severity of hyperglycemia can be increased when Halcinonide is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09091</drugbank-id>
      <name>Tixocortol</name>
      <description>The risk or severity of hyperglycemia can be increased when Tixocortol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09095</drugbank-id>
      <name>Difluocortolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Difluocortolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13158</drugbank-id>
      <name>Clobetasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Clobetasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13223</drugbank-id>
      <name>Fluocortin</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluocortin is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13491</drugbank-id>
      <name>Fluperolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluperolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13664</drugbank-id>
      <name>Formocortal</name>
      <description>The risk or severity of hyperglycemia can be increased when Formocortal is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The risk or severity of hyperglycemia can be increased when Halometasone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13856</drugbank-id>
      <name>Fluclorolone</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluclorolone is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone aceponate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14540</drugbank-id>
      <name>Hydrocortisone butyrate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone butyrate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone cypionate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14543</drugbank-id>
      <name>Hydrocortisone probutate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone probutate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14544</drugbank-id>
      <name>Hydrocortisone valerate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone valerate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Hydrocortisone succinate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00873</drugbank-id>
      <name>Loteprednol</name>
      <description>The risk or severity of hyperglycemia can be increased when Loteprednol is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone phosphate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Fluprednidene acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14643</drugbank-id>
      <name>Methylprednisolone aceponate</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The risk or severity of hyperglycemia can be increased when Methylprednisolone hemisuccinate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisone acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Clocortolone acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Melengestrol acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The risk or severity of hyperglycemia can be increased when Betamethasone phosphate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15566</drugbank-id>
      <name>Prednisolone acetate</name>
      <description>The risk or severity of hyperglycemia can be increased when Prednisolone acetate is combined with Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Levothyroxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>Thyrotropin alfa may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>Liotrix may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>Tiratricol may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>Thyroid, porcine may decrease the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15093</drugbank-id>
      <name>Somapacitan</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Somapacitan.</description>
    </drug-interaction>
  </drug-interactions>
  <sequences>
    <sequence format="FASTA">&gt;A chain
GIVEQCCTSICSLYQLENYCN</sequence>
    <sequence format="FASTA">&gt;B chain
FVNQHLCGSHLVEALYLVCGERGFFYTPKT</sequence>
  </sequences>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>81 C</value>
      <source>Khachidze, D.G. et al., J. Biol. Phys. Chem. 1:64-67 (2001)</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>5808.0</value>
      <source/>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C257H383N65O77S6</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20125</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7672</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>7671</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>5931</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506231</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C00723</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03230</identifier>
    </external-identifier>
    <external-identifier>
      <resource>GenBank</resource>
      <identifier>AY137503</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164744571</identifier>
    </external-identifier>
    <external-identifier>
      <resource>UniProtKB</resource>
      <identifier>Q8HXV2</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000802</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Insulin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>RxCUI</resource>
      <identifier>253182</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic3/novolog.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/pro/humulin-r.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000033</id>
      <name>Insulin receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1839</ref-id>
            <pubmed-id>12970169</pubmed-id>
            <citation>Desbuquois B, Chauvet G, Kouach M, Authier F: Cell itinerary and metabolic fate of proinsulin in rat liver: in vivo and in vitro studies. Endocrinology. 2003 Dec;144(12):5308-21. Epub 2003 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A1840</ref-id>
            <pubmed-id>12038982</pubmed-id>
            <citation>Chen LM, Yang XW, Tang JG: Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.</citation>
          </article>
          <article>
            <ref-id>A1843</ref-id>
            <pubmed-id>17722952</pubmed-id>
            <citation>Bell DS: Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? Drugs. 2007;67(13):1813-27.</citation>
          </article>
          <article>
            <ref-id>A1845</ref-id>
            <pubmed-id>19683471</pubmed-id>
            <citation>Tanti JF, Jager J: Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol. 2009 Dec;9(6):753-62. doi: 10.1016/j.coph.2009.07.004. Epub  2009 Aug 13.</citation>
          </article>
          <article>
            <ref-id>A1847</ref-id>
            <pubmed-id>20230616</pubmed-id>
            <citation>Chiu SL, Cline HT: Insulin receptor signaling in the development of neuronal structure and function. Neural Dev. 2010 Mar 15;5:7. doi: 10.1186/1749-8104-5-7.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P06213" source="Swiss-Prot">
        <name>Insulin receptor</name>
        <general-function>Receptor signaling protein tyrosine kinase activity</general-function>
        <specific-function>Receptor tyrosine kinase which mediates the pleiotropic actions of insulin. Binding of insulin leads to phosphorylation of several intracellular substrates, including, insulin receptor substrates (IRS1, 2, 3, 4), SHC, GAB1, CBL and other signaling intermediates. Each of these phosphorylated proteins serve as docking proteins for other signaling proteins that contain Src-homology-2 domains (SH2 domain) that specifically recognize different phosphotyrosines residues, including the p85 regulatory subunit of PI3K and SHP2. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport. Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway. The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII). Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
        <gene-name>INSR</gene-name>
        <locus>19p13.3-p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>957-979</transmembrane-regions>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>6.18</theoretical-pi>
        <molecular-weight>156331.465</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>INSR</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M10051</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>307070</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1800</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06213</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>INSR_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>IR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036940|Insulin receptor
MATGGRRGAAAAPLLVAVAALLLGAAGHLYPGEVCPGMDIRNNLTRLHELENCSVIEGHL
QILLMFKTRPEDFRDLSFPKLIMITDYLLLFRVYGLESLKDLFPNLTVIRGSRLFFNYAL
VIFEMVHLKELGLYNLMNITRGSVRIEKNNELCYLATIDWSRILDSVEDNYIVLNKDDNE
ECGDICPGTAKGKTNCPATVINGQFVERCWTHSHCQKVCPTICKSHGCTAEGLCCHSECL
GNCSQPDDPTKCVACRNFYLDGRCVETCPPPYYHFQDWRCVNFSFCQDLHHKCKNSRRQG
CHQYVIHNNKCIPECPSGYTMNSSNLLCTPCLGPCPKVCHLLEGEKTIDSVTSAQELRGC
TVINGSLIINIRGGNNLAAELEANLGLIEEISGYLKIRRSYALVSLSFFRKLRLIRGETL
EIGNYSFYALDNQNLRQLWDWSKHNLTITQGKLFFHYNPKLCLSEIHKMEEVSGTKGRQE
RNDIALKTNGDQASCENELLKFSYIRTSFDKILLRWEPYWPPDFRDLLGFMLFYKEAPYQ
NVTEFDGQDACGSNSWTVVDIDPPLRSNDPKSQNHPGWLMRGLKPWTQYAIFVKTLVTFS
DERRTYGAKSDIIYVQTDATNPSVPLDPISVSNSSSQIILKWKPPSDPNGNITHYLVFWE
RQAEDSELFELDYCLKGLKLPSRTWSPPFESEDSQKHNQSEYEDSAGECCSCPKTDSQIL
KELEESSFRKTFEDYLHNVVFVPRKTSSGTGAEDPRPSRKRRSLGDVGNVTVAVPTVAAF
PNTSSTSVPTSPEEHRPFEKVVNKESLVISGLRHFTGYRIELQACNQDTPEERCSVAAYV
SARTMPEAKADDIVGPVTHEIFENNVVHLMWQEPKEPNGLIVLYEVSYRRYGDEELHLCV
SRKHFALERGCRLRGLSPGNYSVRIRATSLAGNGSWTEPTYFYVTDYLDVPSNIAKIIIG
PLIFVFLFSVVIGSIYLFLRKRQPDGPLGPLYASSNPEYLSASDVFPCSVYVPDEWEVSR
EKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKG
FTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMA
AEIADGMAYLNAKKFVHRDLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPV
RWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDN
CPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENKAPESEELEME
FEDMENVPLDRSSHCQREEAGGRDGGSSLGFKRSYEEHIPYTHMNGGKKNGRILTLPRSN
PS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020443|Insulin receptor (INSR)
ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCG
CTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATC
CGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTG
CAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAA
CTCATCATGATCACTGATTACTTGCTGCTCTTCCGGGTCTATGGGCTCGAGAGCCTGAAG
GACCTGTTCCCCAACCTCACGGTCATCCGGGGATCACGACTGTTCTTTAACTACGCGCTG
GTCATCTTCGAGATGGTTCACCTCAAGGAACTCGGCCTCTACAACCTGATGAACATCACC
CGGGGTTCTGTCCGCATCGAGAAGAACAATGAGCTCTGTTACTTGGCCACTATCGACTGG
TCCCGTATCCTGGATTCCGTGGAGGATAATTACATCGTGTTGAACAAAGATGACAACGAG
GAGTGTGGAGACATCTGTCCGGGTACCGCGAAGGGCAAGACCAACTGCCCCGCCACCGTC
ATCAACGGGCAGTTTGTCGAACGATGTTGGACTCATAGTCACTGCCAGAAAGTTTGCCCG
ACCATCTGTAAGTCACACGGCTGCACCGCCGAAGGCCTCTGTTGCCACAGCGAGTGCCTG
GGCAACTGTTCTCAGCCCGACGACCCCACCAAGTGCGTGGCCTGCCGCAACTTCTACCTG
GACGGCAGGTGTGTGGAGACCTGCCCGCCCCCGTACTACCACTTCCAGGACTGGCGCTGT
GTGAACTTCAGCTTCTGCCAGGACCTGCACCACAAATGCAAGAACTCGCGGAGGCAGGGC
TGCCACCAGTACGTCATTCACAACAACAAGTGCATCCCTGAGTGTCCCTCCGGGTACACG
ATGAATTCCAGCAACTTGCTGTGCACCCCATGCCTGGGTCCCTGTCCCAAGGTGTGCCAC
CTCCTAGAAGGCGAGAAGACCATCGACTCGGTGACGTCTGCCCAGGAGCTCCGAGGATGC
ACCGTCATCAACGGGAGTCTGATCATCAACATTCGAGGAGGCAACAATCTGGCAGCTGAG
CTAGAAGCCAACCTCGGCCTCATTGAAGAAATTTCAGGGTATCTAAAAATCCGCCGATCC
TACGCTCTGGTGTCACTTTCCTTCTTCCGGAAGTTACGTCTGATTCGAGGAGAGACCTTG
GAAATTGGGAACTACTCCTTCTATGCCTTGGACAACCAGAACCTAAGGCAGCTCTGGGAC
TGGAGCAAACACAACCTCACCATCACTCAGGGGAAACTCTTCTTCCACTATAACCCCAAA
CTCTGCTTGTCAGAAATCCACAAGATGGAAGAAGTTTCAGGAACCAAGGGGCGCCAGGAG
AGAAACGACATTGCCCTGAAGACCAATGGGGACCAGGCATCCTGTGAAAATGAGTTACTT
AAATTTTCTTACATTCGGACATCTTTTGACAAGATCTTGCTGAGATGGGAGCCGTACTGG
CCCCCCGACTTCCGAGACCTCTTGGGGTTCATGCTGTTCTACAAAGAGGCCCCTTATCAG
AATGTGACGGAGTTCGACGGGCAGGATGCGTGTGGTTCCAACAGTTGGACGGTGGTAGAC
ATTGACCCACCCCTGAGGTCCAACGACCCCAAATCACAGAACCACCCAGGGTGGCTGATG
CGGGGTCTCAAGCCCTGGACCCAGTATGCCATCTTTGTGAAGACCCTGGTCACCTTTTCG
GATGAACGCCGGACCTATGGGGCCAAGAGTGACATCATTTATGTCCAGACAGATGCCACC
AACCCCTCTGTGCCCCTGGATCCAATCTCAGTGTCTAACTCATCATCCCAGATTATTCTG
AAGTGGAAACCACCCTCCGACCCCAATGGCAACATCACCCACTACCTGGTTTTCTGGGAG
AGGCAGGCGGAAGACAGTGAGCTGTTCGAGCTGGATTATTGCCTCAAAGGGCTGAAGCTG
CCCTCGAGGACCTGGTCTCCACCATTCGAGTCTGAAGATTCTCAGAAGCACAACCAGAGT
GAGTATGAGGATTCGGCCGGCGAATGCTGCTCCTGTCCAAAGACAGACTCTCAGATCCTG
AAGGAGCTGGAGGAGTCCTCGTTTAGGAAGACGTTTGAGGATTACCTGCACAACGTGGTT
TTCGTCCCCAGAAAAACCTCTTCAGGCACTGGTGCCGAGGACCCTAGGCCATCTCGGAAA
CGCAGGTCCCTTGGCGATGTTGGGAATGTGACGGTGGCCGTGCCCACGGTGGCAGCTTTC
CCCAACACTTCCTCGACCAGCGTGCCCACGAGTCCGGAGGAGCACAGGCCTTTTGAGAAG
GTGGTGAACAAGGAGTCGCTGGTCATCTCCGGCTTGCGACACTTCACGGGCTATCGCATC
GAGCTGCAGGCTTGCAACCAGGACACCCCTGAGGAACGGTGCAGTGTGGCAGCCTACGTC
AGTGCGAGGACCATGCCTGAAGCCAAGGCTGATGACATTGTTGGCCCTGTGACGCATGAA
ATCTTTGAGAACAACGTCGTCCACTTGATGTGGCAGGAGCCGAAGGAGCCCAATGGTCTG
ATCGTGCTGTATGAAGTGAGTTATCGGCGATATGGTGATGAGGAGCTGCATCTCTGCGTC
TCCCGCAAGCACTTCGCTCTGGAACGGGGCTGCAGGCTGCGTGGGCTGTCACCGGGGAAC
TACAGCGTGCGAATCCGGGCCACCTCCCTTGCGGGCAACGGCTCTTGGACGGAACCCACC
TATTTCTACGTGACAGACTATTTAGACGTCCCGTCAAATATTGCAAAAATTATCATCGGC
CCCCTCATCTTTGTCTTTCTCTTCAGTGTTGTGATTGGAAGTATTTATCTATTCCTGAGA
AAGAGGCAGCCAGATGGGCCGCTGGGACCGCTTTACGCTTCTTCAAACCCTGAGTATCTC
AGTGCCAGTGATGTGTTTCCATGCTCTGTGTACGTGCCGGACGAGTGGGAGGTGTCTCGA
GAGAAGATCACCCTCCTTCGAGAGCTGGGGCAGGGCTCCTTCGGCATGGTGTATGAGGGC
AATGCCAGGGACATCATCAAGGGTGAGGCAGAGACCCGCGTGGCGGTGAAGACGGTCAAC
GAGTCAGCCAGTCTCCGAGAGCGGATTGAGTTCCTCAATGAGGCCTCGGTCATGAAGGGC
TTCACCTGCCATCACGTGGTGCGCCTCCTGGGAGTGGTGTCCAAGGGCCAGCCCACGCTG
GTGGTGATGGAGCTGATGGCTCACGGAGACCTGAAGAGCTACCTCCGTTCTCTGCGGCCA
GAGGCTGAGAATAATCCTGGCCGCCCTCCCCCTACCCTTCAAGAGATGATTCAGATGGCG
GCAGAGATTGCTGACGGGATGGCCTACCTGAACGCCAAGAAGTTTGTGCATCGGGACCTG
GCAGCGAGAAACTGCATGGTCGCCCATGATTTTACTGTCAAAATTGGAGACTTTGGAATG
ACCAGAGACATCTATGAAACGGATTACTACCGGAAAGGGGGCAAGGGTCTGCTCCCTGTA
CGGTGGATGGCACCGGAGTCCCTGAAGGATGGGGTCTTCACCACTTCTTCTGACATGTGG
TCCTTTGGCGTGGTCCTTTGGGAAATCACCAGCTTGGCAGAACAGCCTTACCAAGGCCTG
TCTAATGAACAGGTGTTGAAATTTGTCATGGATGGAGGGTATCTGGATCAACCCGACAAC
TGTCCAGAGAGAGTCACTGACCTCATGCGCATGTGCTGGCAATTCAACCCCAAGATGAGG
CCAACCTTCCTGGAGATTGTCAACCTGCTCAAGGACGACCTGCACCCCAGCTTTCCAGAG
GTGTCGTTCTTCCACAGCGAGGAGAACAAGGCTCCCGAGAGTGAGGAGCTGGAGATGGAG
TTTGAGGACATGGAGAATGTGCCCCTGGACCGTTCCTCGCACTGTCAGAGGGAGGAGGCG
GGGGGCCGGGATGGAGGGTCCTCGCTGGGTTTCAAGCGGAGCTACGAGGAACACATCCCT
TACACACACATGAACGGAGGCAAGAAAAACGGGCGGATTCTGACCTTGCCTCGGTCCAAT
CCTTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00041</identifier>
            <name>fn3</name>
          </pfam>
          <pfam>
            <identifier>PF00757</identifier>
            <name>Furin-like</name>
          </pfam>
          <pfam>
            <identifier>PF01030</identifier>
            <name>Recep_L_domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>insulin receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor substrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor I binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor II binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PTB domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adrenal gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>carbohydrate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of developmental growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glucose import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycogen biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycolytic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of meiotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of respiratory burst</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of female gonad development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction by protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transformation of host cell by virus</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000858</id>
      <name>Insulin-like growth factor 1 receptor</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A174958</ref-id>
            <pubmed-id>19145584</pubmed-id>
            <citation>Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H: Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev. 2009 Jan;25(1):41-9. doi: 10.1002/dmrr.912.</citation>
          </article>
          <article>
            <ref-id>A174961</ref-id>
            <pubmed-id>21219237</pubmed-id>
            <citation>Werner H, Weinstein D, Yehezkel E, Laron Z: Controversies in the use of insulin analogues. Expert Opin Biol Ther. 2011 Feb;11(2):199-209. doi: 10.1517/14712598.2011.540233.</citation>
          </article>
          <article>
            <ref-id>A174883</ref-id>
            <pubmed-id>22420005</pubmed-id>
            <citation>Varewijck AJ, Janssen JA: Insulin and its analogues and their affinities for the IGF1 receptor. Endocr Relat Cancer. 2012 Sep 5;19(5):F63-75. doi: 10.1530/ERC-12-0026. Print 2012 Oct.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08069" source="Swiss-Prot">
        <name>Insulin-like growth factor 1 receptor</name>
        <general-function>Protein tyrosine kinase activity</general-function>
        <specific-function>Receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control. IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway. The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins. In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R. IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R.When present in a hybrid receptor with INSR, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin.</specific-function>
        <gene-name>IGF1R</gene-name>
        <locus>15q26.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>936-959</transmembrane-regions>
        <signal-regions>1-30</signal-regions>
        <theoretical-pi>5.54</theoretical-pi>
        <molecular-weight>154791.73</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5465</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IGF1R</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X04434</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>804990</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1801</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08069</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IGF1R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.10.1</synonym>
          <synonym>IGF-I receptor</synonym>
          <synonym>Insulin-like growth factor I receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001710|Insulin-like growth factor 1 receptor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020490|Insulin-like growth factor 1 receptor (IGF1R)
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGGAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF07714</identifier>
            <name>Pkinase_Tyr</name>
          </pfam>
          <pfam>
            <identifier>PF00757</identifier>
            <name>Furin-like</name>
          </pfam>
          <pfam>
            <identifier>PF01030</identifier>
            <name>Recep_L_domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin receptor substrate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor I binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin-like growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol 3-kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>establishment of cell polarity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exocrine pancreas development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inactivation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin-like growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male sex determination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of muscle cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptidyl-tyrosine autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of steroid hormone biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostate gland epithelium morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autophosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin E</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0002123</id>
      <name>Retinoblastoma-associated protein</name>
      <organism>Humans</organism>
      <actions/>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A176008</ref-id>
            <pubmed-id>7818556</pubmed-id>
            <citation>Radulescu RT, Bellitti MR, Ruvo M, Cassani G, Fassina G: Binding of the LXCXE insulin motif to a hexapeptide derived from retinoblastoma protein. Biochem Biophys Res Commun. 1995 Jan 5;206(1):97-102. doi: 10.1006/bbrc.1995.1014.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P06400" source="Swiss-Prot">
        <name>Retinoblastoma-associated protein</name>
        <general-function>Ubiquitin protein ligase binding</general-function>
        <specific-function>Key regulator of entry into cell division that acts as a tumor suppressor. Promotes G0-G1 transition when phosphorylated by CDK3/cyclin-C. Acts as a transcription repressor of E2F1 target genes. The underphosphorylated, active form of RB1 interacts with E2F1 and represses its transcription activity, leading to cell cycle arrest. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Inhibits the intrinsic kinase activity of TAF1. Mediates transcriptional repression by SMARCA4/BRG1 by recruiting a histone deacetylase (HDAC) complex to the c-FOS promoter. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex (By similarity). In case of viral infections, interactions with SV40 large T antigen, HPV E7 protein or adenovirus E1A protein induce the disassembly of RB1-E2F1 complex thereby disrupting RB1's activity.</specific-function>
        <gene-name>RB1</gene-name>
        <locus>13q14.2</locus>
        <cellular-location>Nucleus</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>8.04</theoretical-pi>
        <molecular-weight>106158.335</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9884</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>RB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M15400</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>190959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P06400</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>RB_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>p105-Rb</synonym>
          <synonym>pp110</synonym>
          <synonym>pRb</synonym>
          <synonym>Rb</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021315|Retinoblastoma-associated protein
MPPKTPRKTAATAAAAAAEPPAPPPPPPPEEDPEQDSGPEDLPLVRLEFEETEEPDFTAL
CQKLKIPDHVRERAWLTWEKVSSVDGVLGGYIQKKKELWGICIFIAAVDLDEMSFTFTEL
QKNIEISVHKFFNLLKEIDTSTKVDNAMSRLLKKYDVLFALFSKLERTCELIYLTQPSSS
ISTEINSALVLKVSWITFLLAKGEVLQMEDDLVISFQLMLCVLDYFIKLSPPMLLKEPYK
TAVIPINGSPRTPRRGQNRSARIAKQLENDTRIIEVLCKEHECNIDEVKNVYFKNFIPFM
NSLGLVTSNGLPEVENLSKRYEEIYLKNKDLDARLFLDHDKTLQTDSIDSFETQRTPRKS
NLDEEVNVIPPHTPVRTVMNTIQQLMMILNSASDQPSENLISYFNNCTVNPKESILKRVK
DIGYIFKEKFAKAVGQGCVEIGSQRYKLGVRLYYRVMESMLKSEEERLSIQNFSKLLNDN
IFHMSLLACALEVVMATYSRSTSQNLDSGTDLSFPWILNVLNLKAFDFYKVIESFIKAEG
NLTREMIKHLERCEHRIMESLAWLSDSPLFDLIKQSKDREGPTDHLESACPLNLPLQNNH
TAADMYLSPVRSPKKKGSTTRVNSTANAETQATSAFQTQKPLKSTSLSLFYKKVYRLAYL
RLNTLCERLLSEHPELEHIIWTLFQHTLQNEYELMRDRHLDQIMMCSMYGICKVKNIDLK
FKIIVTAYKDLPHAVQETFKRVLIKEEEYDSIIVFYNSVFMQRLKTNILQYASTRPPTLS
PIPHIPRSPYKFPSSPLRIPGGNIYISPLKSPYKISEGLPTPTKMTPRSRILVSIGESFG
TSEKFQKINQMVCNSDRVLKRSAEGSNPPKPLKKLRFDIEGSDEADGSKHLPGESKFQQK
LAEMTSTRTRMQKQKMNDSMDTSNKEEK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021316|Retinoblastoma-associated protein (RB1)
ATGCCGCCCAAAACCCCCCGAAAAACGGCCGCCACCGCCGCCGCTGCCGCCGCGGAACCC
CCGGCACCGCCGCCGCCGCCCCCTCCTGAGGAGGACCCAGAGCAGGACAGCGGCCCGGAG
GACCTGCCTCTCGTCAGGCTTGAGTTTGAAGAAACAGAAGAACCTGATTTTACTGCATTA
TGTCAGAAATTAAAGATACCAGATCATGTCAGAGAGAGAGCTTGGTTAACTTGGGAGAAA
GTTTCATCTGTGGATGGAGTATTGGGAGGTTATATTCAAAAGAAAAAGGAACTGTGGGGA
ATCTGTATCTTTATTGCAGCAGTTGACCTAGATGAGATGTCGTTCACTTTTACTGAGCTA
CAGAAAAACATAGAAATCAGTGTCCATAAATTCTTTAACTTACTAAAAGAAATTGATACC
AGTACCAAAGTTGATAATGCTATGTCAAGACTGTTGAAGAAGTATGATGTATTGTTTGCA
CTCTTCAGCAAATTGGAAAGGACATGTGAACTTATATATTTGACACAACCCAGCAGTTCG
ATATCTACTGAAATAAATTCTGCATTGGTGCTAAAAGTTTCTTGGATCACATTTTTATTA
GCTAAAGGGGAAGTATTACAAATGGAAGATGATCTGGTGATTTCATTTCAGTTAATGCTA
TGTGTCCTTGACTATTTTATTAAACTCTCACCTCCCATGTTGCTCAAAGAACCATATAAA
ACAGCTGTTATACCCATTAATGGTTCACCTCGAACACCCAGGCGAGGTCAGAACAGGAGT
GCACGGATAGCAAAACAACTAGAAAATGATACAAGAATTATTGAAGTTCTCTGTAAAGAA
CATGAATGTAATATAGATGAGGTGAAAAATGTTTATTTCAAAAATTTTATACCTTTTATG
AATTCTCTTGGACTTGTAACATCTAATGGACTTCCAGAGGTTGAAAATCTTTCTAAACGA
TACGAAGAAATTTATCTTAAAAATAAAGATCTAGATGCAAGATTATTTTTGGATCATGAT
AAAACTCTTCAGACTGATTCTATAGACAGTTTTGAAACACAGAGAACACCACGAAAAAGT
AACCTTGATGAAGAGGTGAATGTAATTCCTCCACACACTCCAGTTAGGACTGTTATGAAC
ACTATCCAACAATTAATGATGATTTTAAATTCAGCAAGTGATCAACCTTCAGAAAATCTG
ATTTCCTATTTTAACAACTGCACAGTGAATCCAAAAGAAAGTATACTGAAAAGAGTGAAG
GATATAGGATACATCTTTAAAGAGAAATTTGCTAAAGCTGTGGGACAGGGTTGTGTCGAA
ATTGGATCACAGCGATACAAACTTGGAGTTCGCTTGTATTACCGAGTAATGGAATCCATG
CTTAAATCAGAAGAAGAACGATTATCCATTCAAAATTTTAGCAAACTTCTGAATGACAAC
ATTTTTCATATGTCTTTATTGGCGTGCGCTCTTGAGGTTGTAATGGCCACATATAGCAGA
AGTACATCTCAGAATCTTGATTCTGGAACAGATTTGTCTTTCCCATGGATTCTGAATGTG
CTTAATTTAAAAGCCTTTGATTTTTACAAAGTGATCGAAAGTTTTATCAAAGCAGAAGGC
AACTTGACAAGAGAAATGATAAAACATTTAGAACGATGTGAACATCGAATCATGGAATCC
CTTGCATGGCTCTCAGATTCACCTTTATTTGATCTTATTAAACAATCAAAGGACCGAGAA
GGACCAACTGATCACCTTGAATCTGCTTGTCCTCTTAATCTTCCTCTCCAGAATAATCAC
ACTGCAGCAGATATGTATCTTTCTCCTGTAAGATCTCCAAAGAAAAAAGGTTCAACTACG
CGTGTAAATTCTACTGCAAATGCAGAGACACAAGCAACCTCAGCCTTCCAGACCCAGAAG
CCATTGAAATCTACCTCTCTTTCACTGTTTTATAAAAAAGTGTATCGGCTAGCCTATCTC
CGGCTAAATACACTTTGTGAACGCCTTCTGTCTGAGCACCCAGAATTAGAACATATCATC
TGGACCCTTTTCCAGCACACCCTGCAGAATGAGTATGAACTCATGAGAGACAGGCATTTG
GACCAAATTATGATGTGTTCCATGTATGGCATATGCAAAGTGAAGAATATAGACCTTAAA
TTCAAAATCATTGTAACAGCATACAAGGATCTTCCTCATGCTGTTCAGGAGACATTCAAA
CGTGTTTTGATCAAAGAAGAGGAGTATGATTCTATTATAGTATTCTATAACTCGGTCTTC
ATGCAGAGACTGAAAACAAATATTTTGCAGTATGCTTCCACCAGGCCCCCTACCTTGTCA
CCAATACCTCACATTCCTCGAAGCCCTTACAAGTTTCCTAGTTCACCCTTACGGATTCCT
GGAGGGAACATCTATATTTCACCCCTGAAGAGTCCATATAAAATTTCAGAAGGTCTGCCA
ACACCAACAAAAATGACTCCAAGATCAAGAATCTTAGTATCAATTGGTGAATCATTCGGG
ACTTCTGAGAAGTTCCAGAAAATAAATCAGATGGTATGTAACAGCGACCGTGTGCTCAAA
AGAAGTGCTGAAGGAAGCAACCCTCCTAAACCACTGAAAAAACTACGCTTTGATATTGAA
GGATCAGATGAAGCAGATGGAAGTAAACATCTCCCAGGAGAGTCCAAATTTCAGCAGAAA
CTGGCAGAAATGACTTCTACTCGAACACGAATGCAAAAGCAGAAAATGAATGATAGCATG
GATACCTCAAACAAGGAAGAGAAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01858</identifier>
            <name>RB_A</name>
          </pfam>
          <pfam>
            <identifier>PF01857</identifier>
            <name>RB_B</name>
          </pfam>
          <pfam>
            <identifier>PF08934</identifier>
            <name>Rb_C</name>
          </pfam>
          <pfam>
            <identifier>PF11934</identifier>
            <name>DUF3452</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>PML body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Rb-E2F complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>spindle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>SWI/SNF complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>androgen receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>core promoter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription coactivator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor activity, sequence-specific DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transcription factor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin protein ligase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle arrest</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell cycle checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell morphogenesis involved in neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to xenobiotic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>chromatin remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enucleate erythrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glial cell apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatocyte apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitotic sister chromatid cohesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitotic cell cycle checkpoint</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>myoblast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smoothened signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter during mitosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron projection development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic metaphase/anaphase transition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to chromosome, centromeric region</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of centromere complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cohesin localization to chromatin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription involved in G1/S transition of mitotic cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sister chromatid biorientation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striated muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0001123</id>
      <name>Carboxypeptidase E</name>
      <organism>Humans</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185351</ref-id>
            <pubmed-id>24843127</pubmed-id>
            <citation>Liew CW, Assmann A, Templin AT, Raum JC, Lipson KL, Rajan S, Qiang G, Hu J, Kawamori D, Lindberg I, Philipson LH, Sonenberg N, Goldfine AB, Stoffers DA, Mirmira RG, Urano F, Kulkarni RN: Insulin regulates carboxypeptidase E by modulating translation initiation scaffolding protein eIF4G1 in pancreatic beta cells. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):E2319-28. doi: 10.1073/pnas.1323066111. Epub 2014 May 19.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16870" source="Swiss-Prot">
        <name>Carboxypeptidase E</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Removes residual C-terminal Arg or Lys remaining after initial endoprotease cleavage during prohormone processing. Processes proinsulin.</specific-function>
        <gene-name>CPE</gene-name>
        <locus>4q32.3</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>4.78</theoretical-pi>
        <molecular-weight>53150.185</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2303</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CPE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X51405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>29667</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16870</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CBPE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.17.10</synonym>
          <synonym>Carboxypeptidase H</synonym>
          <synonym>CPE</synonym>
          <synonym>CPH</synonym>
          <synonym>Enkephalin convertase</synonym>
          <synonym>Prohormone-processing carboxypeptidase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002234|Carboxypeptidase E
MAGRGGSALLALCGALAACGWLLGAEAQEPGAPAAGMRRRRRLQQEDGISFEYHRYPELR
EALVSVWLQCTAISRIYTVGRSFEGRELLVIELSDNPGVHEPGEPEFKYIGNMHGNEAVG
RELLIFLAQYLCNEYQKGNETIVNLIHSTRIHIMPSLNPDGFEKAASQPGELKDWFVGRS
NAQGIDLNRNFPDLDRIVYVNEKEGGPNNHLLKNMKKIVDQNTKLAPETKAVIHWIMDIP
FVLSANLHGGDLVANYPYDETRSGSAHEYSSSPDDAIFQSLARAYSSFNPAMSDPNRPPC
RKNDDDSSFVDGTTNGGAWYSVPGGMQDFNYLSSNCFEITVELSCEKFPPEETLKTYWED
NKNSLISYLEQIHRGVKGFVRDLQGNPIANATISVEGIDHDVTSAKDGDYWRLLIPGNYK
LTASAPGYLAITKKVAVPYSPAAGVDFELESFSERKEEEKEELMEWWKMMSETLNF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016324|Carboxypeptidase E (CPE)
ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGG
TGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGC
CGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGC
GAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGG
CGCAGCTTCGAGGGCCGGGAGCTCCTGGTCATCGAGCTGTCCGACAACCCTGGCGTCCAT
GAGCCTGGTGAGCCTGAATTTAAATACATTGGGAATATGCATGGGAATGAGGCTGTTGGA
CGAGAACTGCTCATTTTCTTGGCCCAGTACCTATGCAACGAATACCAGAAGGGGAACGAG
ACAATTGTCAACCTGATCCACAGTACCCGCATTCACATCATGCCTTCCCTGAACCCAGAT
GGCTTTGAGAAGGCAGCGTCTCAGCCTGGTGAACTCAAGGACTGGTTTGTGGGTCGAAGC
AATGCCCAGGGAATAGATCTGAACCGGAACTTTCCAGACCTGGATAGGATAGTGTACGTG
AATGAGAAAGAAGGTGGTCCAAATAATCATCTGTTGAAAAATATGAAGAAAATTGTGGAT
CAAAACACAAAGCTTGCTCCTGAGACCAAGGCTGTCATTCATTGGATTATGGATATTCCT
TTTGTGCTTTCTGCCAATCTCCATGGAGGAGACCTTGTGGCCAATTATCCATATGATGAG
ACGCGGAGTGGTAGTGCTCACGAATACAGCTCCTCCCCAGATGACGCCATTTTCCAAAGC
TTGGCCCGGGCATACTCTTCTTTCAACCCGGCCATGTCTGACCCCAATCGGCCACCATGT
CGCAAGAATGATGATGACAGCAGCTTTGTAGATGGAACCACCAACGGTGGTGCTTGGTAC
AGCGTACCTGGAGGGATGCAAGACTTCAATTACCTTAGCAGCAACTGTTTTGAGATCACC
GTGGAGCTTAGCTGTGAGAAGTTCCCACCTGAAGAGACTCTGAAGACCTACTGGGAGGAT
AACAAAAACTCCCTCATTAGCTACCTTGAGCAGATACACCGAGGAGTTAAAGGATTTGTC
CGAGACCTTCAAGGTAACCCAATTGCGAATGCCACCATCTCCGTGGAAGGAATAGACCAC
GATGTTACATCCGCAAAGGATGGTGATTACTGGAGATTGCTTATACCTGGAAACTATAAA
CTTACAGCCTCAGCTCCAGGCTATCTGGCAATAACAAAGAAAGTGGCAGTTCCTTACAGC
CCTGCTGCTGGGGTTGATTTTGAACTGGAGTCATTTTCTGAAAGGAAAGAAGAGGAGAAG
GAAGAATTGATGGAATGGTGGAAAATGATGTCAGAAACTTTAAATTTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00246</identifier>
            <name>Peptidase_M14</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cell adhesion molecule binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metallocarboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurexin family protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type carboxypeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac left ventricle morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="4">
      <id>BE0001183</id>
      <name>Insulin-degrading enzyme</name>
      <organism>Humans</organism>
      <actions>
        <action>cleavage</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A176011</ref-id>
            <pubmed-id>19785409</pubmed-id>
            <citation>Amata O, Marino T, Russo N, Toscano M: Human insulin-degrading enzyme working mechanism. J Am Chem Soc. 2009 Oct 21;131(41):14804-11. doi: 10.1021/ja9037142.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P14735" source="Swiss-Prot">
        <name>Insulin-degrading enzyme</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>Plays a role in the cellular breakdown of insulin, IAPP, glucagon, bradykinin, kallidin and other peptides, and thereby plays a role in intercellular peptide signaling. Degrades amyloid formed by APP and IAPP. May play a role in the degradation and clearance of naturally secreted amyloid beta-protein by neurons and microglia.(Microbial infection) The membrane-associated isoform acts as an entry receptor for varicella-zoster virus (VZV).</specific-function>
        <gene-name>IDE</gene-name>
        <locus>10q23-q25</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>6.74</theoretical-pi>
        <molecular-weight>117967.49</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5381</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>IDE</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M21188</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184556</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14735</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IDE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.24.56</synonym>
          <synonym>Abeta-degrading protease</synonym>
          <synonym>Insulin protease</synonym>
          <synonym>Insulinase</synonym>
          <synonym>Insulysin</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037135|Insulin-degrading enzyme
MRYRLAWLLHPALPSTFRSVLGARLPPPERLCGFQKKTYSKMNNPAIKRIGNHITKSPED
KREYRGLELANGIKVLLISDPTTDKSSAALDVHIGSLSDPPNIAGLSHFCEHMLFLGTKK
YPKENEYSQFLSEHAGSSNAFTSGEHTNYYFDVSHEHLEGALDRFAQFFLCPLFDESCKD
REVNAVDSEHEKNVMNDAWRLFQLEKATGNPKHPFSKFGTGNKYTLETRPNQEGIDVRQE
LLKFHSAYYSSNLMAVCVLGRESLDDLTNLVVKLFSEVENKNVPLPEFPEHPFQEEHLKQ
LYKIVPIKDIRNLYVTFPIPDLQKYYKSNPGHYLGHLIGHEGPGSLLSELKSKGWVNTLV
GGQKEGARGFMFFIINVDLTEEGLLHVEDIILHMFQYIQKLRAEGPQEWVFQECKDLNAV
AFRFKDKERPRGYTSKIAGILHYYPLEEVLTAEYLLEEFRPDLIEMVLDKLRPENVRVAI
VSKSFEGKTDRTEEWYGTQYKQEAIPDEVIKKWQNADLNGKFKLPTKNEFIPTNFEILPL
EKEATPYPALIKDTAMSKLWFKQDDKFFLPKACLNFEFFSPFAYVDPLHCNMAYLYLELL
KDSLNEYAYAAELAGLSYDLQNTIYGMYLSVKGYNDKQPILLKKIIEKMATFEIDEKRFE
IIKEAYMRSLNNFRAEQPHQHAMYYLRLLMTEVAWTKDELKEALDDVTLPRLKAFIPQLL
SRLHIEALLHGNITKQAALGIMQMVEDTLIEHAHTKPLLPSQLVRYREVQLPDRGWFVYQ
QRNEVHNNCGIEIYYQTDMQSTSENMFLELFCQIISEPCFNTLRTKEQLGYIVFSGPRRA
NGIQGLRFIIQSEKPPHYLESRVEAFLITMEKSIEDMTEEAFQKHIQALAIRRLDKPKKL
SAECAKYWGEIISQQYNFDRDNTEVAYLKTLTKEDIIKFYKEMLAVDAPRRHKVSVHVLA
REMDSCPVVGEFPCQNDINLSQAPALPQPEVIQNMTEFKRGLPLFPLVKPHINFMAAKL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016342|Insulin-degrading enzyme (IDE)
ATGAGCAAACTTTGGTTCAAACAAGATGATAAGTTTTTTTTGCCGAAGGCTTGTCTCAAC
TTTGAATTTTTCAGCCCATTTGCTTATGTGGACCCCTTGCACTGTAACATGGCCTATTTG
TACCTTGAGCTCCTCAAAGACTCACTCAACGAGTATGCATATGCAGCAGAGCTAGCAGGC
TTGAGCTATGATCTCCAAAATACCATCTATGGGATGTATCTTTCAGTGAAAGGTTACAAT
GACAAGCAGCCAATTTTACTAAAGAAGATTATTGAGAAAATGGCTACCTTTGAGATTGAT
GAAAAAAGATTTGAAATTATCAAAGAAGCATATATGCGATCTCTTAACAATTTCCGGGCT
GAACAGCCTCACCAGCATGCCATGTACTACCTCCGCTTGCTGATGACTGAAGTGGCCTGG
ACTAAAGATGAGTTAAAAGAAGCTCTGGATGATGTAACCCTTCCTCGCCTTAAGGCCTTC
ATACCTCAGCTCCTGTCACGGCTGCACATTGAAGCCCTTCTCCATGGAAACATAACAAAG
CAGGCTGCATTAGGAATTATGCAGATGGTTGAAGACACCCTCATTGAACATGCTCATACC
AAACCTCTCCTTCCAAGTCAGCTGGTTCGGTATAGAGAAGTTCAGCTCCCTGACAGAGGA
TGGTTTGTTTATCAGCAGAGAAATGAAGTTCACAATAACTGTGGCATCGAGATATACTAC
CAAACAGACATGCAAAGCACCTCAGAGAATATGTTTCTGGAGCTCTTCTGTCAGATTATC
TCGGAACCTTGCTTCAACACCCTGCGCACCAAGGAGCAGTTGGGCTATATCGTCTTCAGC
GGGCCACGTCGAGCTAATGGCATACAGGGCTTGAGATTCATCATCCAGTCAGAAAAGCCA
CCTCACTACCTAGAAAGCAGAGTGGAAGCTTTCTTAATTACCATGGAAAAGTCCATAGAG
GACATGACAGAAGAGGCCTTCCAAAAACACATTCAGGCATTAGCAATTCGTCGACTAGAC
AAACCAAAGAAGCTATCTGCTGAGTGTGCTAAATACTGGGGAGAAATCATCTCCCAGCAA
TATAATTTTGACAGAGATAACACTGAGGTTGCATATTTAAAGACACTTACCAAGGAAGAT
ATCATCAAATTCTACAAGGAAATGTTGGCAGTAGATGCTCCAAGGAGACATAAGGTATCC
GTCCATGTTCTTGCCAGGGAAATGGATTCTTGTCCTGTTGTTGGAGAGTTCCCATGTCAA
AATGACATAAATTTGTCACAAGCACCAGCCTTGCCACAACCTGAAGTGATTCAGAACATG
ACCGAATTCAAGCGTGGTCTGCCACTGTTTCCCCTTGTGAAACCACATATTAACTTCATG
GCTGCAAAACTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00675</identifier>
            <name>Peptidase_M16</name>
          </pfam>
          <pfam>
            <identifier>PF05193</identifier>
            <name>Peptidase_M16_C</name>
          </pfam>
          <pfam>
            <identifier>PF16187</identifier>
            <name>Peptidase_M16_M</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosolic proteasome complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisomal matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>peroxisome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-amyloid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-endorphin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycoprotein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>insulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metalloendopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ubiquitin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>beta-amyloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bradykinin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>determination of adult lifespan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein heterooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homotetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis involved in cellular protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ubiquitin homeostasis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="5">
      <id>BE0002124</id>
      <name>Neuroendocrine convertase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L5707</ref-id>
            <title>Uniprot P16519</title>
            <url>https://www.uniprot.org/uniprot/P16519</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P16519" source="Swiss-Prot">
        <name>Neuroendocrine convertase 2</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Responsible for the release of glucagon from proglucagon in pancreatic A cells.</specific-function>
        <gene-name>PCSK2</gene-name>
        <locus>20p11.2</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-25</signal-regions>
        <theoretical-pi>6.47</theoretical-pi>
        <molecular-weight>70564.735</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8744</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PCSK2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J05252</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189652</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P16519</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NEC2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.94</synonym>
          <synonym>KEX2-like endoprotease 2</synonym>
          <synonym>NEC 2</synonym>
          <synonym>NEC2</synonym>
          <synonym>PC2</synonym>
          <synonym>Prohormone convertase 2</synonym>
          <synonym>Proprotein convertase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004166|Neuroendocrine convertase 2
MKGGCVSQWKAAAGFLFCVMVFASAERPVFTNHFLVELHKGGEDKARQVAAEHGFGVRKL
PFAEGLYHFYHNGLAKAKRRRSLHHKQQLERDPRVKMALQQEGFDRKKRGYRDINEIDIN
MNDPLFTKQWYLINTGQADGTPGLDLNVAEAWELGYTGKGVTIGIMDDGIDYLHPDLASN
YNAEASYDFSSNDPYPYPRYTDDWFNSHGTRCAGEVSAAANNNICGVGVAYNSKVAGIRM
LDQPFMTDIIEASSISHMPQLIDIYSASWGPTDNGKTVDGPRELTLQAMADGVNKGRGGK
GSIYVWASGDGGSYDDCNCDGYASSMWTISINSAINDGRTALYDESCSSTLASTFSNGRK
RNPEAGVATTDLYGNCTLRHSGTSAAAPEAAGVFALALEANLGLTWRDMQHLTVLTSKRN
QLHDEVHQWRRNGVGLEFNHLFGYGVLDAGAMVKMAKDWKTVPERFHCVGGSVQDPEKIP
STGKLVLTLTTDACEGKENFVRYLEHVQAVITVNATRRGDLNINMTSPMGTKSILLSRRP
RDDDSKVGFDKWPFMTTHTWGEDARGTWTLELGFVGSAPQKGVLKEWTLMLHGTQSAPYI
DQVVRDYQSKLAMSKKEELEEELDEAVERSLKSILNKN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011539|Neuroendocrine convertase 2 (PCSK2)
ATGGTTTTTGCATCTGCTGAGCGACCGGTCTTCACGAATCATTTTCTTGTGGAGTTGCAT
AAAGGGGGAGAGGACAAAGCTCGCCAAGTTGCAGCAGAACACGGCTTTGGAGTCCGAAAG
CTTCCCTTTGCTGAAGGTCTGTACCACTTTTATCACAATGGCCTTGCAAAGGCCAAGAGA
AGACGCAGCCTACACCACAAGCAGCAGCTGGAGAGAGACCCCAGGGTAAAGATGGCTTTG
CAGCAGGAAGGATTTGACCGAAAAAAGCGAGGTTACAGAGACATCAATGAGATCGACATC
AACATGAACGATCCTCTTTTTACAAAGCAGTGGTATCTGATCAATACTGGGCAAGCTGAT
GGCACTCCTGGCCTTGATTTGAATGTGGCTGAAGCCTGGGAGCTGGGATACACAGGGAAA
GGTGTTACCATTGGAATTATGGATGATGGGATTGACTATCTCCACCCGGACCTGGCCTCC
AACTATAATGCCGAAGCAAGTTACGACTTCAGCAGCAACGACCCCTATCCTTACCCTCGG
TACACAGATGACTGGTTTAACAGCCACGGGACCCGATGTGCAGGAGAAGTTTCTGCTGCC
GCCAACAACAATATCTGTGGAGTTGGAGTAGCATACAACTCCAAGGTTGCAGGCATCCGG
ATGCTGGACCAGCCATTCATGACAGACATCATCGAGGCCTCCTCCATCAGTCATATGCCA
CAGCTGATTGACATCTACAGCGCCAGCTGGGGCCCCACAGACAACGGCAAGACAGTGGAT
GGGCCCCGGGAGCTCACGCTGCAGGCCATGGCCGATGGCGTGAACAAGGGCCGCGGCGGC
AAAGGCAGCATCTACGTGTGGGCCTCCGGGGACGGCGGCAGCTATGACGACTGCAACTGC
GACGGCTACGCCTCCAGCATGTGGACCATCTCCATCAACTCAGCCATCAACGACGGCAGG
ACTGCCCTGTACGACGAGAGCTGCTCTTCCACCTTGGCTTCCACCTTCAGCAACGGGAGG
AAAAGGAACCCCGAGGCCGGTGTGGCAACCACAGATTTGTACGGCAACTGCACTCTGAGG
CATTCTGGGACATCTGCAGCTGCCCCCGAGGCAGCTGGTGTGTTTGCACTGGCTCTGGAG
GCTAACCTGGGTCTGACCTGGCGGGACATGCAGCATCTGACTGTGCTCACCTCCAAACGG
AACCAGCTTCACGACGAGGTCCATCAGTGGCGGCGCAATGGGGTCGGCCTGGAATTTAAT
CACCTCTTTGGCTACGGGGTCCTTGATGCAGGTGCCATGGTGAAAATGGCTAAAGACTGG
AAAACCGTGCCTGAGAGATTCCACTGTGTGGGAGGCTCCGTGCAGGACCCTGAGAAAATA
CCATCCACTGGCAAGTTGGTGCTGACACTCACAACCGACGCCTGTGAGGGGAAGGAAAAT
TTTGTCCGCTACCTGGAGCATGTCCAGGCTGTCATCACGGTCAACGCAACCAGAAGAGGA
GACCTGAACATCAACATGACTTCCCCTATGGGCACCAAGTCCATTTTGCTGAGCCGGCGT
CCAAGGGATGACGACTCCAAGGTGGGCTTTGACAAGTGGCCTTTCATGACCACTCACACG
TGGGGGGAAGACGCCCGAGGCACCTGGACCCTGGAGCTGGGATTTGTCGGCAGCGCCCCG
CAGAAGGGGGTGCTGAAGGAGTGGACCCTGATGCTGCATGGCACTCAGAGTGCCCCGTAC
ATCGACCAGGTGGTGCGGGATTACCAGTCCAAGTTGGCCATGTCCAAGAAAGAGGAGCTG
GAGGAAGAGCTGGACGAAGCCGTGGAGAGAAGCCTGAAAAGCATCCTTAACAAGAACTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00082</identifier>
            <name>Peptidase_S8</name>
          </pfam>
          <pfam>
            <identifier>PF01483</identifier>
            <name>P_proprotein</name>
          </pfam>
          <pfam>
            <identifier>PF16470</identifier>
            <name>S8_pro-domain</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>enkephalin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>islet amyloid polypeptide processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein autoprocessing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="6">
      <id>BE0002125</id>
      <name>Neuroendocrine convertase 1</name>
      <organism>Humans</organism>
      <actions>
        <action>activator</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L5710</ref-id>
            <title>Uniprot P29120</title>
            <url>https://www.uniprot.org/uniprot/P29120</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P29120" source="Swiss-Prot">
        <name>Neuroendocrine convertase 1</name>
        <general-function>Serine-type endopeptidase activity</general-function>
        <specific-function>Involved in the processing of hormone and other protein precursors at sites comprised of pairs of basic amino acid residues. Substrates include POMC, renin, enkephalin, dynorphin, somatostatin, insulin and AGRP.</specific-function>
        <gene-name>PCSK1</gene-name>
        <locus>5q15-q21</locus>
        <cellular-location>Cytoplasmic vesicle</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>5.84</theoretical-pi>
        <molecular-weight>84150.92</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8743</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PCSK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X64810</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>35318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2382</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P29120</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NEC1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.4.21.93</synonym>
          <synonym>NEC 1</synonym>
          <synonym>NEC1</synonym>
          <synonym>PC1</synonym>
          <synonym>Prohormone convertase 1</synonym>
          <synonym>Proprotein convertase 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004168|Neuroendocrine convertase 1
MERRAWSLQCTAFVLFCAWCALNSAKAKRQFVNEWAAEIPGGPEAASAIAEELGYDLLGQ
IGSLENHYLFKHKNHPRRSRRSAFHITKRLSDDDRVIWAEQQYEKERSKRSALRDSALNL
FNDPMWNQQWYLQDTRMTAALPKLDLHVIPVWQKGITGKGVVITVLDDGLEWNHTDIYAN
YDPEASYDFNDNDHDPFPRYDPTNENKHGTRCAGEIAMQANNHKCGVGVAYNSKVGGIRM
LDGIVTDAIEASSIGFNPGHVDIYSASWGPNDDGKTVEGPGRLAQKAFEYGVKQGRQGKG
SIFVWASGNGGRQGDNCDCDGYTDSIYTISISSASQQGLSPWYAEKCSSTLATSYSSGDY
TDQRITSADLHNDCTETHTGTSASAPLAAGIFALALEANPNLTWRDMQHLVVWTSEYDPL
ANNPGWKKNGAGLMVNSRFGFGLLNAKALVDLADPRTWRSVPEKKECVVKDNDFEPRALK
ANGEVIIEIPTRACEGQENAIKSLEHVQFEATIEYSRRGDLHVTLTSAAGTSTVLLAERE
RDTSPNGFKNWDFMSVHTWGENPIGTWTLRITDMSGRIQNEGRIVNWKLILHGTSSQPEH
MKQPRVYTSYNTVQNDRRGVEKMVDPGEEQPTQENPKENTLVSKSPSSSSVGGRRDELEE
GAPSQAMLRLLQSAFSKNSPPKQSPKKSPSAKLNIPYENFYEALEKLNKPSQLKDSEDSL
YNDYVDVFYNTKPYKHRDDRLLQALVDILNEEN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016688|Neuroendocrine convertase 1 (PCSK1)
ATGGAGCGAAGAGCCTGGAGTCTGCAGTGCACTGCTTTCGTCCTCTTTTGCGCTTGGTGT
GCACTGAACAGTGCAAAAGCGAAAAGGCAATTTGTCAATGAATGGGCAGCGGAGATCCCC
GGGGGCCCGGAAGCAGCCTCGGCCATCGCCGAGGAGCTGGGCTATGACCTTTTGGGTCAG
ATTGGTTCACTTGAAAATCACTACTTATTCAAACATAAAAACCACCCCAGAAGGTCTCGA
AGGAGTGCCTTTCATATCACTAAGAGATTATCTGATGATGATCGTGTGATATGGGCTGAA
CAACAGTATGAAAAAGAAAGAAGTAAACGTTCAGCTCTAAGGGACTCAGCACTAAATCTC
TTCAATGATCCCATGTGGAATCAGCAATGGTACTTGCAAGATACCAGGATGACGGCAGCC
CTGCCCAAGCTGGACCTTCATGTGATACCTGTTTGGCAAAAAGGCATTACGGGCAAAGGA
GTTGTTATCACCGTACTGGATGATGGTTTGGAGTGGAATCACACGGACATTTATGCCAAC
TATGATCCAGAGGCTAGCTATGATTTTAATGATAATGACCATGATCCATTTCCCCGATAT
GATCCCACAAACGAGAACAAACACGGGACCAGATGTGCAGGAGAAATTGCCATGCAAGCA
AATAATCACAAATGCGGGGTTGGAGTTGCATACAATTCCAAAGTTGGAGGCATAAGAATG
CTGGATGGCATTGTGACGGATGCTATTGAGGCCAGTTCAATTGGATTCAATCCTGGACAC
GTGGATATTTACAGTGCAAGCTGGGGCCCTAATGATGATGGGAAAACTGTGGAGGGGCCT
GGCCGGCTAGCCCAGAAGGCTTTTGAATATGGTGTCAAACAGGGGAGACAGGGGAAGGGG
TCCATCTTCGTCTGGGCTTCGGGAAACGGGGGGCGTCAGGGAGATAATTGTGACTGTGAT
GGCTACACAGACAGCATCTACACCATCTCCATCAGCAGTGCCTCCCAGCAAGGCCTATCC
CCCTGGTACGCTGAGAAGTGCTCCTCCACACTGGCCACCTCTTACAGCAGCGGAGATTAC
ACCGACCAGAGAATCACGAGCGCTGACCTGCACAATGACTGCACGGAGACGCACACAGGC
ACCTCGGCCTCTGCACCTCTGGCTGCTGGCATCTTCGCTCTGGCCCTGGAAGCAAACCCA
AATCTCACCTGGCGAGATATGCAGCACCTGGTTGTCTGGACCTCTGAGTATGACCCGCTG
GCCAATAACCCTGGATGGAAAAAGAATGGAGCAGGCTTGATGGTGAATAGTCGATTTGGA
TTTGGCTTGCTAAATGCCAAAGCTCTGGTGGATTTAGCTGACCCCAGGACCTGGAGGAGC
GTGCCTGAGAAGAAAGAGTGTGTTGTAAAGGACAATGACTTTGAGCCCAGAGCCCTGAAA
GCTAATGGAGAAGTTATCATTGAAATTCCAACAAGAGCTTGTGAAGGACAAGAAAATGCT
ATCAAGTCCCTGGAGCATGTACAATTTGAAGCAACAATTGAATATTCCCGAAGAGGAGAC
CTTCATGTCACACTTACTTCTGCTGCTGGAACTAGCACTGTGCTCTTGGCTGAAAGAGAA
CGGGATACATCTCCTAATGGCTTTAAGAATTGGGACTTCATGTCTGTTCACACATGGGGA
GAGAACCCTATAGGTACTTGGACTTTGAGAATTACAGACATGTCTGGAAGAATTCAAAAT
GAAGGAAGAATTGTGAACTGGAAGCTGATTTTGCACGGGACCTCTTCTCAGCCAGAGCAT
ATGAAGCAGCCTCGTGTGTACACGTCCTACAACACTGTTCAGAATGACAGAAGAGGGGTG
GAGAAGATGGTGGATCCAGGGGAGGAGCAGCCCACACAAGAGAACCCTAAGGAGAACACC
CTGGTGTCCAAAAGCCCCAGCAGCAGCAGCGTAGGGGGCCGGAGGGATGAGTTGGAGGAG
GGAGCCCCTTCCCAGGCCATGCTGCGACTCCTGCAAAGTGCTTTCAGTAAAAACTCACCG
CCAAAGCAATCACCAAAGAAGTCCCCAAGTGCAAAGCTCAACATCCCTTATGAAAACTTC
TACGAAGCCCTGGAAAAGCTGAACAAACCTTCCCAGCTTAAAGACTCTGAAGACAGTCTG
TATAATGACTATGTTGATGTTTTTTATAACACTAAACCTTACAAGCACAGAGACGACCGG
CTGCTTCAAGCTCTGGTGGACATTCTGAATGAGGAAAATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00082</identifier>
            <name>Peptidase_S8</name>
          </pfam>
          <pfam>
            <identifier>PF01483</identifier>
            <name>P_proprotein</name>
          </pfam>
          <pfam>
            <identifier>PF16470</identifier>
            <name>S8_pro-domain</name>
          </pfam>
          <pfam>
            <identifier>PF12177</identifier>
            <name>Proho_convert</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>transport vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serine-type endopeptidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide hormone processing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="7">
      <id>BE0002433</id>
      <name>Cytochrome P450 1A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inducer</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A181319</ref-id>
            <pubmed-id>1562279</pubmed-id>
            <citation>Barnett CR, Wilson J, Wolf CR, Flatt PR, Ioannides C: Hyperinsulinaemia causes a preferential increase in hepatic P4501A2 activity. Biochem Pharmacol. 1992 Mar 17;43(6):1255-61. doi: 10.1016/0006-2952(92)90500-i.</citation>
          </article>
          <article>
            <ref-id>A181322</ref-id>
            <pubmed-id>12130701</pubmed-id>
            <citation>Pass GJ, Becker W, Kluge R, Linnartz K, Plum L, Giesen K, Joost HG: Effect of hyperinsulinemia and type 2 diabetes-like hyperglycemia on expression of hepatic cytochrome p450 and glutathione s-transferase isoforms in a New Zealand obese-derived mouse backcross population. J Pharmacol Exp Ther. 2002 Aug;302(2):442-50. doi: 10.1124/jpet.102.033553.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05177" source="Swiss-Prot">
        <name>Cytochrome P450 1A2</name>
        <general-function>Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.</specific-function>
        <gene-name>CYP1A2</gene-name>
        <locus>15q24</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.43</theoretical-pi>
        <molecular-weight>58293.76</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2596</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP1A2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z00036</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05177</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP1A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYPIA2</synonym>
          <synonym>Cytochrome P(3)450</synonym>
          <synonym>Cytochrome P450 4</synonym>
          <synonym>Cytochrome P450-P3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004778|Cytochrome P450 1A2
MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2)
ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC
TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA
AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC
CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT
GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG
CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC
CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC
CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC
CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG
GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT
GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG
AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC
ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC
CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC
CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC
CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC
ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG
AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT
GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC
TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC
ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG
TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT
AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG
GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG
TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG
CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>demethylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron carrier activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cadmium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dibenzo-p-dioxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epoxygenase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lung development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>methylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monocarboxylic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>omega-hydroxylase P450 pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative deethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>porphyrin-containing compound metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>post-embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to immobilization stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength>unknown</induction-strength>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>